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REFORMING REGENERATIVE MEDICINE 
REGULATION 
Sarah Duranske* 
INTRODUCTION 
The gods were angry. Prometheus and his brother had endowed the 
creatures of the earth with gifts to help them survive and prosper: 
speed, cunning, strength. But, in error, Prometheus had overlooked 
man—a naked and weak creature that would surely perish unless 
gifted with something truly remarkable. So, Prometheus snuck onto 
Mount Olympus and stole fire from the gods. This gift he provided to 
man. But the gods disapproved—with fire, man could challenge their 
superiority. As punishment, Prometheus was chained to a rock. Each 
day, an eagle tore apart and devoured part of his liver. Each night, the 
liver regrew, ensuring that his torture would be unending.1 
Thus begins the story of regenerative medicine. 
When humans are wounded, our bodies heal through a mixture of 
scar tissue formation and tissue regeneration.2 We are familiar with 
scar tissue formation—special cells migrate to the site of the injury 
and produce proteins that support the tissue.3 But we have another 
wound-healing ability demonstrated by Prometheus—the ability of 
some cells to divide to produce more of themselves.4 In humans, the 
                                                                                                                 
* Thomas C. Grey Fellow and Lecturer at Law, Stanford Law School. I wish to thank Hank T. Greely, 
Michelle M. Mello, Norman Spaulding, W. Nicholson Price II, Yanbai Andrea Yang, Rebecca Wolitz, 
Alix Rogers, Ji Seon Song, and the participants of the 2017 Grey Fellows Forum for their invaluable 
comments. 
 1. Mark Cartwright, Prometheus, ANCIENT HIST. ENCYCLOPEDIA (Apr. 20, 2013), 
https://www.ancient.eu/Prometheus/ [https://perma.cc/KRM7-HX58]. 
 2. See Nat’l Insts. of Health, Regenerative Medicine, RES. PORTFOLIO ONLINE REPORTING TOOLS, 
https://report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=62&key=R|[num]|R [https://perma.cc/A
7BM-7SJW] (last updated Oct. 2010) [hereinafter NIH Fact Sheets: Regenerative Medicine]; Univ. of 
Ill. at Chi., Mechanism that Limits Scar Formation Discovered, SCIENCEDAILY (June 11, 2010), 
https://www.sciencedaily.com/releases/2010/06/100610154459.htm [https://perma.cc/5LKX-AQW9]. 
 3. Juan Diego Naranjo et al., Regenerative Medicine: Lessons from Mother Nature, 11 
REGENERATIVE MED. 767, 768 (2016); Univ. of Ill. at Chi., supra note 2. 
 4. SCOTT F. GILBERT, DEVELOPMENTAL BIOLOGY, ch. 18 (6th ed., 2000) (ebook), 
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natural ability to regenerate tissue is limited. Only a few specific 
tissues such as bone marrow, liver, and the outer layer of skin 
demonstrate this ability.5 
The ability to regenerate tissue is even more amazing in other 
species. The axolotl is a Mexican salamander known for its ability to 
regenerate lost limbs. The axolotl regenerates tissues in a way that 
humans cannot: the cells near the site of the injury lose their 
specialization and then morph into the cells needed to regrow the 
missing limb.6 
The salamander’s regenerative abilities inspired scientists. Could 
the same mechanism work in humans? In early experiments, 
scientists harvested stem cells from tissues in the human body and 
inserted the cells into an injury site.7 Because stem cells retain the 
ability to multiply (called “proliferation”) and turn into different cell 
types (called “differentiation”), scientists hoped that the stem cells 
would cause the creation of new tissues. The results, however, were 
“disappointing at best.”8 The interactions between stem cells, the 
microenvironment, the disease state, and dosing concerns stymied 
early efforts to create functional tissue.9 
But early experiments have progressed into increasingly successful 
applications.10 Today, some regenerative medicine therapies are 
commercially available, with others at various stages in the research 
pipeline.11 And the field is broader than just stem cell therapies. 
Regenerative medicine is defined as the branch of medicine that 
develops methods to regrow, repair, or replace damaged or diseased 
                                                                                                                 
https://www.ncbi.nlm.nih.gov/books/NBK9971/ [https://perma.cc/TX9T-NRD2]; Naranjo, supra note 3, 
at 767. 
 5. Ricardo Londono & Stephen F. Badylak, Biologic Scaffolds for Regenerative Medicine: 
Mechanisms of In vivo Remodeling, 43 ANNALS OF BIOMEDICAL ENGINEERING 577, 582 (2014). 
 6. GILBERT, supra note 4; Naranjo, supra note 3, at 769. 
 7. ANGELO S. MAO & DAVID J. MOONEY, Regenerative Medicine: Current Therapies and Future 
Directions, 112 PNAS 14452, 14452 (2015), http://www.pnas.org/content/112/47/14452 
[https://perma.cc/J6RC-2EHT]. 
 8. Naranjo, supra note 3, at 770. 
 9. Id. 
 10. Id. 
 11. MAO & MOONEY, supra note 7, at 14452; NIH Fact Sheets: Regenerative Medicine, supra 
note 2. 
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cells or tissues. 12 It includes a variety of approaches, such as 
transplanting cells to promote healing, editing genes in cells to attack 
cancer, and even building organs from biological materials.13 
Regulating regenerative medicine therapies is no easy task. 
Finding a balance between competing interests–enabling timely 
access for needy patients while simultaneously ensuring a positive 
benefit/risk profile and promoting the development of beneficial 
innovations–is hard enough at any given point in time. But add in 
constantly advancing scientific knowledge and increasing 
commercialization opportunities, and the regulatory system struggles 
to keep pace. 
As new potential therapies have emerged and challenged the 
existing regulatory structure, stakeholders have prodded Congress 
and the Food and Drug Administration (FDA) for reforms to make 
the pathway to the marketplace less rigorous.14 These efforts include 
enacted laws, such as a regenerative medicine provision in the 21st 
Century Cures Act, congressional bills that have been introduced but 
died, and policy whitepapers. But others oppose loosening the 
regulatory framework and argue that the current level of premarket 
testing for safety and efficacy is needed both to ensure public health 
and to advance the field of regenerative medicine by generating 
important clinical data.15 Still others advocate for a middle path that 
advances some therapies while protecting the public from the most 
egregious risks.16 I evaluate these reform proposals based on the dual 
goals of regulating medical products based on risk: protecting the 
public by limiting access to therapies where the risks outweigh the 
benefits, and promoting innovations that improve public health. 
                                                                                                                 
 12. See NIH Fact Sheets: Regenerative Medicine, supra note 2. 
 13. Naranjo, supra note 3, at 772. 
 14. See Maude L. Cuchiara, Jackie K. Olive & Kirstin Matthews, Regulating the Therapeutic 
Translation of Regenerative Medicine, 15 EXPERT OPINION ON BIOLOGICAL THERAPY 1387, 1388 
(2015), http://www.tandfonline.com/doi/full/10.1517/14712598.2015.1064895 [https://perma.cc/2C2X-
VM3M].; Robin Downey & Rose Geransar, Stem Cell Research, Publics’ and Stakeholder Views, 16 
HEALTH L. REV. 69, 69 (2008). 
 15. Dina Gould Halme & David A. Kessler, FDA Regulation of Stem-Cell–Based Therapies, 355 
NEW ENG. J. MED. 1730, 1730 (2006). 
 16. Cuchiara, Olive & Matthews, supra note 14, at 1388–89. 
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I first argue that proposals to speed FDA approval through 
adaptive licensing are premature. These proposals, which differ in the 
details but share the same core features, would have the FDA 
approve regenerative medicine therapies based on less robust clinical 
evidence of safety and efficacy, but restrict the initial patient 
population and impose post-marketing obligations on the sponsor to 
gather evidence of the product’s safety and efficacy in “real world” 
conditions. Although adaptive licensing’s goals of accelerating 
access to therapies and generating real world evidence are 
sympathetic, the proposals are premature. Applying a theoretical 
framework of adaptive management that identifies appropriate 
conditions for iterative regulation highlights the fatal problem with 
adaptive licensing for regenerative medicine therapies: the risk of 
patient harm is too high. Existing evidence from other medical 
products approved under expedited pathways is instructive: it 
demonstrates that the third and final phase of clinical trials is vital to 
determine the safety and efficacy of a medical product, and that 
products approved under expedited pathways have more safety 
problems than those approved under the traditional process. 
Second, I consider reform proposals for low and moderate-risk 
regenerative medicine therapies. Based on recent scientific literature, 
I argue that the current laws and regulations set an appropriate 
framework for the regulation of regenerative medicine therapies and 
support incremental reforms. 
This current climate of reform creates an opportunity to analyze 
the success of the current regime in furthering the dual goals of 
medical product regulation: protecting public health and encouraging 
beneficial innovations. It invites us to consider whether other 
frameworks can better resolve the tension between the short-term 
goals of enabling access to therapies for needy patients with the 
longer-term goals of advancing society’s understanding of the 
science and medicine of regenerative therapies. 
Health law scholars writing on regenerative medicine have largely 
ignored the broader questions raised by the current reform climate 
and have focused instead on the legal and normative issues raised in a 
4
Georgia State University Law Review, Vol. 34, Iss. 3 [2018], Art. 3
https://readingroom.law.gsu.edu/gsulr/vol34/iss3/3
2018] REFORMING REGENERATIVE MEDICINE REGULATION 635 
2014 case regarding the authority of the FDA to regulate a subsection 
of therapies that use a patient’s own cells as source materials.17 In 
that regard, this Article makes a unique contribution to the literature 
by using theories of risk regulation to evaluate the current structure 
and proposed reforms. In doing so, I seek to offer a considered and 
thorough legal and normative analysis of the existing regulatory 
framework and reform proposals that can meaningfully inform the 
policy debate. 
This Article has four parts. Part I describes the regenerative 
medicine industry and the existing federal regulatory structure that 
governs regenerative medicine therapies. Part II addresses the need 
for regulation as well as the critiques of the current framework. Part 
III analyzes proposals for progressive licensing of higher-risk 
regenerative medicine therapies regulated as biologics. Part IV 
evaluates reforms for regenerative medicine therapies regulated as 
human cell and tissue products. 
I.   Regulating Regenerative Medicine 
Scores of regenerative medicine products using regular cells from 
the human body (called “somatic” cells) are commercially available, 
and hundreds of clinical trials are investigating stem cell therapies.18 
Yet the fact that only one type of stem cell product has received FDA 
approval has motivated some industry representatives and patient 
advocates to call for reforms to speed regenerative medicine products 
to market. The existing multi-tiered regulatory structure, however, 
already allows for tailored regulation depending on a therapy’s risk 
of harm, and such tailoring includes less burdensome pathways to 
                                                                                                                 
 17. However, two important exceptions exist. See generally Barbara von Tigerstrom, Revising the 
Regulation of Stem Cell Based Therapies: Critical Assessment of Potential Models, 70 FOOD & DRUG 
L.J. 315 (2015) (examining exemptions from regulation in Australia and the European Union); see also 
Margaret Foster Riley, Twenty-First-Century Technology with Twentieth-Century Baggage: FDA 
Regulation of Regenerative Medicine, in FDA IN THE 21ST CENTURY: THE CHALLENGES OF 
REGULATING DRUGS AND NEW TECHNOLOGIES 455, 466 (I. Glenn Cohen & Holly F. Lynch, eds., 2015) 
(noting that altering the minimal manipulation and homologous use standards may speed access to 
regenerative medicine therapies). 
 18. MAO & MOONEY, supra note 7, at 14452; see generally Clinicaltrials.gov, U.S. NAT’L LIBRARY 
OF MED., https://clinicaltrials.gov/ [https://perma.cc/YC38-82HD] (last visited Jan. 6, 2018) (providing 
“a database of privately and publicly funded clinical studies conducted around the world”). 
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market for lower-risk therapies. In this section, I describe the state of 
the regenerative medicine industry and the harms the therapies can 
cause. I then explain the current regulatory structure and its critiques. 
A.   The State of the Industry 
Regenerative medicine therapies seek to harness the body’s ability 
to heal itself. Stem cell therapies epitomize regenerative medicine 
therapies because of their potential to heal and to harm. The potential 
of stem cells to regrow, repair, or replace damaged or diseased cells, 
organs, or tissues motivated early researchers and continues to excite 
today.19 Thousands of stem cell trials have been completed, and 
many hundreds more are ongoing.20 In these trials, investigators 
study how new combinations of stem cell products and delivery 
mechanisms affect a range of diseases and conditions.21 Yet, in spite 
of this progress, the FDA has approved only one type of stem cell 
product: hematopoietic (blood forming) stem cells from cord blood to 
reconstitute a patient’s blood and immune system after myeloablative 
treatments like radiation.22 
                                                                                                                 
 19. Erin Allday, ‘Super exciting’ Results in Stem Cell Therapy Trial, SFGATE (Oct. 2, 2017, 
9:09AM), http://www.sfgate.com/health/article/Super-exciting-results-in-stem-cell-therapy-
12245199.php [https://perma.cc/6YG3-7HA5] (reporting on Asterias Biotherapeutics’ Phase 1/2 clinical 
trial results which demonstrated that four out of six paralyzed patients receiving a stem-cell derived 
injection showed improvement in motor levels); Asterias Announces Two Significant Developments for 
Spinal Cord Injury Program, ASTERIAS BIOTHERAPEUTICS (Oct. 2, 2017), 
http://www.asteriasbiotherapeutics.com/inv_news_releasre_text.php?releaseid=2303887&date=October
+02%2C+2017&title=Asterias+Announces+Two+Significant+Developments+for+Spinal+Cord+Injury
+Program [https://perma.cc/29N7-RT2T]. 
 20. See Clinicaltrials.gov, supra note 18 (searching the term “stem cell,” limited to recruiting, 
enrolling, and active interventional (or clinical) trials returned 1,518 results, and the same search for 
completed trials returned 1,746 results). 
 21. One well-publicized trial transplanted autologous iPSC-derived retinal cells to treat age-related 
macular degeneration. Erin Kimbrel & Robert Lanza, Pluripotent Stem Cells: The Last 10 Years, 11 
REGENERATIVE. MED. 831, 834–36 (2016). The transplant into the first patient went well, but the trial 
was suspended before transplant into the second patient because the sample was found to contain a 
genetic mutation that could increase the risk that the patient would develop cancer from the transplant. 
Id. Separately, a Phase 1 trial tested the safety and feasibility of human embryonic stem cell-derived 
cardiac progenitor cells embedded onto a patch. Id. The patch was then embedded into the heart during 
surgery. Id. This clinical trial was based on preclinical evidence that the cells engrafted and then 
differentiated into cardiac muscle cells in preclinical models. Id. Another trial is planned to study the 
safety and effectiveness of a drug delivery device implanted under the skin that releases human 
embryonic stem cell-derived pancreas cells to treat type I diabetes. Id. 
 22. The product Hemacord provides hematopoietic (blood-forming) stem cells from a donor’s 
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Excitement over stem cells has also led to the exploitation of 
desperate patients. Stem cell clinics offer unproven and unregulated 
stem cell treatments to cure a variety of ailments, so long as a patient 
can pay the out-of-pocket costs. In a 2016 study, Professors Paul 
Knoepfler and Leigh Turner identified 351 businesses engaged in 
direct-to-consumer marketing of stem cell interventions at 570 
clinics.23 The majority of these businesses marketed autologous 
interventions, where the stem cells used for treatment came from the 
patients’ own tissues.24 The most common source for the autologous 
stem cells was adipose (fat) tissue, followed by bone marrow. Stem 
cell clinics promote their treatments for a variety of diseases and 
conditions, ranging from autism and Alzheimer’s disease to sports 
injuries and cosmetic surgery.25 The cost of treatment can range from 
$5,000 to $20,000.26 
Although stem cell-based therapies have garnered much attention, 
therapies that use other cell and tissue sources also fall under the 
rubric of regenerative medicine therapies.27 Several products that use 
somatic cells or cell-derivatives are commercially available. For 
example, Carticel, an FDA-approved product to treat articular 
cartilage defects (injuries to the slick cartilage at knee joints and 
other joints), uses chondrocytes (the cell type in healthy cartilage) 
harvested from the patient’s cartilage, expanded in a lab, and re-
inserted at the site of injury.28 The cosmetic product laViv uses 
                                                                                                                 
allogeneic cord blood to reconstitute the patient’s blood and immune systems after myeloablative 
treatment (such as radiation). MAO & MOONEY, supra note 7, at 14452; Approved Cellular and Gene 
Therapy Products, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProAppro/ 
[https://perma.cc/DJ5H-FE44] (last updated Sept. 20, 2017). Similar transplants occur using stem cells 
from a donor’s own cord blood. See Kang-Hsi Wu et al., Letter to the Editor: Autologous Cord Blood 
Transplantation in a Child with Stage 4 Neuroblastoma, 48 BONE MARROW TRANSPLANTATION 317, 
318 (2013). 
 23. Leigh Turner & Paul Knoepfler, Selling Stem Cells in the USA: Assessing the Direct-to-
Consumer Industry, 19 CELL STEM CELL 154, 154 (2016). 
 24. Id. at 155. 
 25. Id. at 155–56. 
 26. Usha Lee McFarling, FDA Weighs Crackdown that Could Shut Hundreds of Stem Cell Clinics, 
STAT (Sept. 9, 2016), https://www.statnews.com/2016/09/09/stem-cell-fda-
hearing/ [https://perma.cc/E8GU-HHGW]. 
 27. MAO & MOONEY, supra note 7, at 14452. 
 28. Id. 
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autologous fibroblasts (the main cell found in connective tissue, 
sourced from the patient) to improve the appearance of nasolabial 
fold wrinkles in adults.29 The product Apligraf uses human foreskin 
fibroblasts to create wound-healing grafts.30 
Rounding out the major types of regenerative medicine therapies 
are gene editing products and bioengineering products. The FDA 
approved the first gene therapy in the United States in August 2017.31 
Kymriah, a cell-based CAR-T gene therapy from Novartis, is created 
from a patient’s own T-cells.32 The patient’s T-cells are collected and 
then genetically modified to include a new gene.33 When the cells are 
infused back into the patient, the modified gene causes the cell to 
target and kill certain leukemia cells.34 Other gene therapies remain 
in the research pipeline. A large number of gene editing trials modify 
the genes in T-cells to alter their susceptibility to autoimmune 
viruses, like HIV, or to enhance their ability to recognize and bind to 
diseased cells.35 
Researchers are also working to manufacture human tissue, even 
entire organs. Bioengineering, or tissue engineering, is the process of 
creating cell-based products for the structural repair of various tissue 
defects.36 At the Wake Forest Institute for Regenerative Medicine, 
Dr. Anthony Atala has tested 3-D printing technology that has 
printed cartilage, bone, and muscle tissue that was then successfully 
implanted into rodents.37 Dr. Laura Niklason has commenced a Phase 
                                                                                                                 
 29. Id. at 14452–53. 
 30. Id. 
 31. Press Release, U.S. Food & Drug Admin., FDA Approval Brings First Gene Therapy to the 
United States (Aug. 30, 2017), 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm 
[https://perma.cc/D6X2-CBHW]. 
 32. In Historic First, FDA Approves Gene Therapy for Acute Lymphoblastic Leukemia, MANAGED 
CARE (Aug. 30, 2017), https://www.managedcaremag.com/news/historic-first-fda-approves-gene-
therapy-acute-lymphoblastic-leukemia [https://perma.cc/68DZ-7TEH]. 
 33. Id. 
 34. Id. 
 35. Kuang-Yui Chen & Paul S. Knoepfler, To CRISPR and Beyond: The Evolution of Genome 
Editing in Stem Cells, 11 REGENERATIVE MED. 801, 809 (2016). 
 36. The Comm. for Advanced Therapies (CAT) & The CAT Sci. Secretariat, Challenges with 
Advanced Therapy Medicinal Products and How to Meet Them, Perspectives, 9 NATURE REVS. 195, 
196 (2010). 
 37. Mathew Shaer, Need a New Organ? Surgeon Anthony Atala Sees a Future Where You Can 
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3 clinical trial testing bioengineered blood vessels grown from 
human cells that are seeded into a biodegradable scaffold, and given 
nutrients and mechanical signals to coax them to grow into a new 
blood vessel.38 
B.   Regulatory Framework 
As the primary agency in the United States regulating medical 
products, the FDA is tasked with ensuring the safety and efficacy of 
regenerative medicine therapies. It regulates these therapies based on 
three goals: (1) to prevent the use of contaminated cells and tissues 
with the potential for transmitting infectious diseases including AIDS 
and hepatitis; (2) to prevent improper handling that might 
contaminate or damage cells and tissues; and (3) to ensure that 
clinical safety and effectiveness is demonstrated for cells and tissues 
that are highly processed, are used for atypical functions, are 
combined with non-tissue components, or are used for metabolic 
purposes.39 
Prior to 1997, federal regulation of cell and tissue products was 
fragmented. The FDA viewed organ and tissue transplants as simply 
part of the practice of medicine.40 Because the FDA does not regulate 
the practice of medicine, but instead has jurisdiction over the tools 
used by doctors in the practice of medicine, it declined to assert 
authority over tissue transplants.41 But two trends started to blur the 
line between the practice of medicine and the FDA’s jurisdiction: 
first, technological advances allowed for the storing, transporting, 
                                                                                                                 
Simply Print It Out, SMITHSONIAN MAG. (Dec. 2016), http://www.smithsonianmag.com/innovation/mira
cle-maker-anthony-atala-winner-smithsonian-ingenuity-awards-2016-life-sciences-180961121/ 
[https://perma.cc/R4Y8-4EVV]. 
 38. 37: Humacyte, CNBC (June 7, 2016, 6:03 AM), http://www.cnbc.com/2016/06/06/humacyte-
2016-disruptor-50.html [https://perma.cc/7GQM-2S63]. 
 39. Martha A. Wells, Overview of FDA Regulation of Human Cellular and Tissue-Based Products, 
52 FOOD & DRUG L.J. 401, 406 (1997). 
 40. Frank A. Duckworth, Regulation of Human Tissues and Organs, 46 FOOD DRUG COSMETIC L.J. 
1, 12 (1991). 
 41. Id. But see Patricia J. Zettler, Toward Coherent Federal Oversight of Medicine, 52 SAN DIEGO L. 
REV. 427, 427–28 (2015) (arguing that, contrary to the conventional wisdom that states regulate medical 
practice while the federal government regulates medical products, the federal government does—and 
should—regulate medical practice when public health is affected). 
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and preserving of organs and tissues, which added new variables to 
transplant procedures; and second, the AIDS crisis heightened the 
consequences of communicable disease transmission.42 
Thus, in 1997, the FDA proposed its current approach to 
regulation for articles “containing or consisting of human cells or 
tissues that are intended for implantation, transplantation, infusion, or 
transfer into a human recipient.”43 The regulatory regime was 
designed to “improve the protection of the public health without 
imposing unnecessary restrictions on research, development, or the 
availability of new products.”44 The FDA delineated three levels of 
regulation for human cell and tissue products based on the product’s 
risk-level: (1) products not subject to regulation; (2) products 
regulated as human cell, tissues, or cellular- or tissue-based products 
(“cell or tissue products”) under Section 361 of the Public Health 
Service Act (PHSA); and (3) products regulated as biological drugs 
under Section 351 of the PHSA.45 The FDA’s current solution is 
therefore a three-tiered framework based on a therapy’s risks of 
communicable disease, safety, and effectiveness.46 This section 
provides an overview of the framework from the lowest level of 
regulation to the highest. 
1.   Same Surgical Procedure Exemption 
The lowest tier of regulation is no regulation. The FDA does not 
regulate cells and tissues that are removed from a patient and 
transplanted back into that patient during a single surgical 
procedure.47 The FDA reasoned that the communicable disease risks, 
as well as safety and effectiveness risks, from these procedures 
would be no different than those typically associated with surgery.48 
                                                                                                                 
 42. Duckworth, supra note 40. 
 43. 21 C.F.R. § 1271.3(d) (2017). 
 44. Human Cells, Tissues, and Cellular and Tissue-Based Products, 66 Fed. Reg. 5447 (Jan. 19, 
2001) (codified at 21 C.F.R. pts 207, 807, 1271). 
 45. Wells, supra note 39, at 406. 
 46. Id. The current three-tiered system was introduced in 1997, with the final rule becoming 
effective in 2005. Id. 
 47. 21 C.F.R. § 1271.15(b) (2017). 
 48. 21 C.F.R. § 1271.3(d); U.S. FOOD & DRUG ADMIN., DOC. NO. 97N-0068, PROPOSED APPROACH 
10
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And, because surgery is part of the practice of medicine, and 
therefore generally regulated by the state and not the federal 
government, the FDA exempted these procedures from its rules.49 
For policy reasons, the FDA also excludes cells or tissues removed 
from a donor and immediately transferred to an intimate sexual 
partner.50 
Some articles are not covered in the FDA’s human cell and tissue 
regulatory scheme because they are covered by other regulations.51 
These include whole organs; minimally manipulated bone marrow; 
blood products such as whole blood, platelets, and plasma; and 
extracts such as human milk, collagen, and growth factors.52 
2.   Section 361 Products 
The FDA implemented an intermediate tier of regulation for cell or 
tissue products between 1997 and 2005. The thrust of the new rules 
was to address those products whose main risk to public health and 
safety was the transmission of communicable diseases. The rules 
were promulgated under the authority of section 361 of the PHSA, 
which provides jurisdiction for “regulations . . . necessary to prevent 
the introduction, transmission, or spread of communicable 
diseases . . . .”53 
Only those cell or tissue products that meet four criteria qualify as 
“section 361” products under this intermediate tier of regulation. 
First, the product can be no more than minimally manipulated.54 This 
means that the product cannot be processed in a manner that alters 
                                                                                                                 
TO REGULATION OF CELLULAR AND TISSUE-BASED PRODUCTS 12 (1997) [hereinafter PROPOSED 
APPROACH TO REGULATION OF CELLULAR AND TISSUE-BASED PRODUCTS]. 
 49. See, e.g., Zettler, supra note 41, at 436–37, 482–93. 
 50. 21 C.F.R. § 1271.15(e); see also PROPOSED APPROACH TO REGULATION OF CELLULAR AND 
TISSUE-BASED PRODUCTS, supra note 48, at 13. 
 51. 21 C.F.R. § 1271.3(d)(1–8). 
 52. Id. 
 53. 42 U.S.C. § 264(a) (2012). 
 54. James R. Ravitz, Naomi J. L. Halpern & Emily M. Leongini, FDA Announces “New” 
Framework to Regulate Stem Cell Therapies and Regenerative Medicine, LEXOLOGY (Sept. 8, 2017), 
https://www.lexology.com/library/detail.aspx?g=bb78fe6e-1cdd-499a-907d-087ebb5fc28f 
[https://perma.cc/Q7N3-FX8Q]. 
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the cells’ or tissues’ relevant characteristics.55 Second, the product 
must be intended for homologous use, which means that the cells or 
tissues must perform the same basic function in the recipient as in the 
donor.56 Third, the product’s manufacturer must not combine the 
cells or tissues with any other article except for “water, crystalloids, 
or a sterilizing, preserving, or storage agent, provided that the 
addition of water, crystalloids, or the sterilizing, preserving or storage 
agent does not raise any new clinical safety concerns with respect to 
the [cell or tissue product].”57 Fourth, the product must either (a) not 
have a systemic effect and not be dependent on the metabolic activity 
of living cells for its primary function, or (b) if it does have a 
systemic effect or is dependent upon the metabolic activity of living 
cells for its primary function, it must be for autologous use, for 
allogeneic use in a close relative, or for reproductive use.58 
The obligations for establishments that manufacture section 361 
products are relatively light compared to those for biologics 
manufacturers. The establishments must register with the FDA; 
follow procedures for testing, screening, and determining donor 
eligibility; and follow current Good Tissue Practices to prevent the 
introduction, transmission, or spread of communicable disease.59 
3.   Biologics/Drugs 
If a regenerative medicine product does not meet either the same 
surgical procedure exemption or the requirements of section 361, 
then the product is regulated as a biologic under section 351 of the 
Public Health Service Act.60 Section 351 covers biological products, 
                                                                                                                 
 55. U.S. FOOD & DRUG ADMIN., MINIMAL MANIPULATION OF HUMAN CELLS, TISSUES, AND 
CELLULAR AND TISSUE-BASED PRODUCTS: DRAFT GUIDANCE FOR INDUSTRY AND FOOD 
AND DRUG ADMINISTRATION STAFF 2 (2014) [hereinafter FDA DRAFT GUIDANCE ON MINIMAL 
MANIPULATION]. 
 56. U.S. FOOD & DRUG ADMIN., HOMOLOGOUS USE OF HUMAN CELLS, TISSUES, AND CELLULAR 
AND TISSUE-BASED PRODUCTS: DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF (2015) [hereinafter 
FDA DRAFT GUIDANCE ON HOMOLOGOUS USE]. 
 57. 21 C.F.R. § 1271.10(a)(3) (2004). 
 58. Id. § 1271.10. 
 59. Id. § 1271.1(a). 
 60. 42 U.S.C. § 262 (Supp. 2017). A limited number of cell or tissue products are regulated as 
medical devices, but because the majority of cell or tissue products are biologics or human cell or tissue 
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including blood-derived products and products containing cells or 
microorganisms.61 The FDA considers biological products a subset of 
drugs, so the FDA’s drug regulations also apply to section 351 
products.62 Thus, the term “drug” is used in this article to cover 
biologic products as well. If a biologic is licensed under section 351, 
it does not need to be separately licensed as a new drug.63 
Biological products must receive a license before they can be 
introduced into interstate commerce.64 The biologics license 
application must demonstrate that the biological product is safe, pure, 
and potent, and that the facility in which it is manufactured meets 
standards designed to ensure the product’s continued safety, purity, 
and potency.65 Like a new drug application, a biologics license 
application usually requires data from preclinical or clinical trials.66 
In order to initiate a clinical trial, the biologic’s sponsor must submit 
an Investigational New Drug application before proceeding with the 
clinical trial.67 
The clinical study definitions for biologics are identical to those 
for new drugs.68 As such, biologics regulated under section 351 
generally go through three phases of clinical trials unless they follow 
an expedited path. The typical path to approval starts with a small 
(twenty to eighty patients) phase 1 clinical trial designed to evaluate 
safety and the product’s mechanism of action.69 Phase 2 trials are 
                                                                                                                 
products, a thorough examination of the medical device scheme is outside the scope of this article. 
 61. Id.; U.S. FOOD & DRUG ADMIN., Frequently Asked Questions About Therapeutic Biological 
Products, 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Appro
valApplications/TherapeuticBiologicApplications/ucm113522.htm. [https://perma.cc/FP7B-EKLD] (last 
updated July 7, 2015). 
 62. U.S. FOOD & DRUG ADMIN., supra note 61. 
 63. 42 U.S.C. § 262(j). 
 64. Id. § 262(a)(1). 
 65. Id. § 262(a)(2)(C)(i). 
 66. 21 C.F.R. § 601.2(a) (2016); U.S. FOOD & DRUG ADMIN., APPLICATION TO MARKET A NEW OR 
ABBREVIATED NEW DRUG OR BIOLOGIC FOR HUMAN USE (2017) 
https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/ucm082348.pdf 
[https://perma.cc/J4QP-A89J]. 
 67. See U.S. FOOD & DRUG ADMIN., supra note 61. 
 68. 21 C.F.R. § 312.2(a) (2009) (“Except as provided in this section, this part applies to all clinical 
investigations of products that are subject to section 505 of the Federal Food, Drug, and Cosmetic Act 
[New Drugs] or to the licensing provisions of the Public Health Service Act.”). 
 69. Id. § 312.21(a). 
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designed to evaluate the effectiveness of a drug and to determine 
common short-term side effects and risks.70 Phase 2 studies usually 
involve no more than several hundred patients. Large-scale phase 3 
studies gather sufficient data on the product’s safety and efficacy to 
support extrapolating the results to the general population.71 In 
addition to the clinical data, a biologics license application also must 
contain a significant amount of information about the manufacturing 
process, operating procedures, and equipment used in the product’s 
manufacture.72 
Approved biologics must adhere to current good manufacturing 
requirements.73 These detailed and comprehensive requirements 
address many aspects of the manufacturing process, personnel 
qualifications, equipment validation, standard operating procedures, 
quality control processes, change and document controls, packaging 
and labeling, purchasing controls, acceptance activities, and record 
keeping.74 The manufacturers are also required to notify the FDA of 
certain changes in manufacturing and of adverse events.75 
C.   A Lifecycle Approach 
The FDA approves a new drug or biologic for marketing based on 
the pretrial and clinical trial evidence submitted by the sponsor.76 
This traditional approval paradigm has two drastically distinct stages: 
pre-approval and post-approval.77 Before a product is approved, the 
only patients who may access it are those in a clinical trial who have 
given informed consent.78 But after the FDA approves a biologic, it 
                                                                                                                 
 70. Id. § 312.21(b). 
 71. Id. § 312.21(c). 
 72. Id. § 601.2(a). 
 73. Facts About the Current Good Manufacturing Practices (CGMPs), U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/ucm169105.htm 
[https://perma.cc/S2LF-7YRV] (last visited Oct. 6, 2017). 
 74. 21 C.F.R. §§ 211, 601, & 820 (2017). 
 75. Id. § 314.80 (2017) (reporting for drugs); id. § 600.80 (2010) (reporting for biologics); 
id. § 601.12 (2012) (reporting requirements). 
 76. Rebecca Eisenberg, The Role of the FDA in Innovation Policy, 13 MICH. TELECOMM. & TECH. 
L. REV. 366, 370 (2007). 
 77. Hans-Georg Eichler et al., Adaptive Licensing: Taking the Next Step in the Evolution of Drug 
Approval, 91 CLINICAL PHARMACOLOGY & THERAPEUTICS 426, 426 (2012). 
 78. Id. 
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generally becomes widely available.79 In the most common scenario, 
patients can access the biologic without any particular eligibility 
requirements, and may even obtain it for unapproved conditions 
through an off-label prescription.80 
This traditional approval paradigm has suffered extensive 
criticism, because relying on pre-market evidence alone fails to give 
an accurate picture of a medical product’s risks and benefits.81 
Clinical trials are designed with narrow and specific inclusion 
criteria, but post approval use includes patients with different risk 
factors such as age, medication use, and chronic conditions.82 
Indications for use in clinical trials are specific and well-monitored, 
but indications for use in the marketplace can be off-label and 
untested in clinical trials.83 And because clinical trials are relatively 
short, they can fail to reveal the long-term risks or effects of the 
product.84 
In response, Congress and the FDA have begun shifting towards a 
lifecycle approach to drug evaluation where risks and benefits are 
monitored throughout a drug’s lifecycle, including after approval.85 
This approach is reflected in the FDA’s programs that expedite 
approval of new drugs with an accompanying commitment from the 
sponsor to provide postmarket evidence of safety and effectiveness. 
For regenerative medicine therapies, the 21st Century Cures Act 
created an accelerated approval pathway for “regenerative medicine 
advanced therapies” (RMAT).86 To qualify as an RMAT, a therapy 
                                                                                                                 
 79. Id. 
 80. Id. 
 81. Shannon Gibson & Trudo Lemmens, Overcoming “Premarket Syndrome,” in FDA IN THE 21ST 
CENTURY: THE CHALLENGES OF REGULATING DRUGS AND NEW TECHNOLOGIES 269, 269 (I. Glenn 
Cohen & Holly F. Lynch, eds., 2015) [hereinafter Overcoming Premarket Syndrome]; Charles 
Steenburg, The Food and Drug Administration’s Use of Postmarketing (Phase IV) Study Requirements: 
Exception to the Rule?, 61 FOOD & DRUG L.J. 295, 297 (2006) (discussing the shortcomings of 
premarket clinical trials). 
 82. U.S. FOOD & DRUG ADMIN., STRUCTURED APPROACH TO BENEFIT-RISK ASSESSMENT IN DRUG 
REGULATORY DECISION-MAKING: DRAFT PDUFA V IMPLEMENTATION PLAN 9 (2013). 
 83. Margaret Foster Riley, An Unfulfilled Promise: Changes Needed to the Drug Approval Process 
to Make Personalized Medicine a Reality, 70 FOOD & DRUG L.J. 289, 297 (2016). 
 84. Eisenberg, supra note 76, at 376. 
 85. Overcoming Premarket Syndrome, supra note 81, at 269; Eisenberg, supra note 76, at 376; U.S. 
FOOD & DRUG ADMIN., supra note 82, at 9. 
 86. 21st Century Cures Act, sec. 3033, 130 Stat. 1101 (2016) (codified at 21 U.S.C. § 356). 
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must first meet the statutory definition of a regenerative medicine 
therapy, defined to include “cell therapy, therapeutic tissue 
engineering products, human cell and tissue products, and 
combination products using any such therapies or products, except 
for those regulated solely under section 361 of the Public Health 
Service Act and part 1271 of title 21, Code of Federal Regulations.”87 
Thus, foundationally, this section only addresses those products that 
are not regulated as section 361 products. The therapy must also be 
intended to treat, modify, reverse, or cure a serious or life-threatening 
disease or condition,88 and be supported by “preliminary clinical 
evidence” that indicates that the therapy has the potential to address 
unmet medical needs for the disease or condition.89 The FDA has 
begun implementing this provision and, as of July 2017, had 
approved four requests to qualify products under the section.90 
An RMAT is entitled to the same benefits for expedited 
development and review as drugs that receive Breakthrough Therapy 
designation are,91 including interactions with the FDA throughout the 
development process, advice to ensure that the development program 
for obtaining nonclinical and clinical data is efficient, and helping to 
ensure that clinical trial design is as efficient as practicable.92 
In addition, a therapy designated as an RMAT may be eligible for 
Priority Review and Accelerated Approval.93 This means that an 
RMAT may receive approval based on surrogate or intermediate 
endpoints “reasonably likely to predict long-term clinical benefit,” or 
on data obtained from a “meaningful number of sites, including 
through expansion to additional sites.”94 
                                                                                                                 
 87. The Act does not cover section 361 products, but covers only those products otherwise regulated 
as a drug or biologic. 21 U.S.C. § 356(g)(8) (Supp. 2016). 
 88. 21 U.S.C. § 356(g)(2)(B). 
 89. Id. § 356(g)(2)(C). 
 90. Scott Gottlieb, How FDA Plans to Help Consumers Capitalize on Advances in Science, U.S. 
FOOD & DRUG ADMIN., FDA VOICE (July 7, 2017), 
https://blogs.fda.gov/fdavoice/index.php/2017/07/how-fda-plans-to-help-consumers-capitalize-on-
advances-in-science/ [https://perma.cc/2D6Y-X73Y]. 
 91. 21 U.S.C. § 356(g)(1); see id. § 356(a)(3)(B). 
 92. Id. § 356(a)(3)(B). 
 93. Id. §§ 356(c), 356(g)(6)(B). 
 94. Id. §§ 356(c), 356(g)(6)(B). 
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The RMAT approval pathway is the same as the Accelerated 
Approval pathway for drugs in most regards, but the Accelerated 
Approval pathway does not contain the option of approval based on 
data from “a meaningful number of sites.”95 This may reflect a 
liberalization of acceptable forms of scientific evidence based on the 
promise of research using electronic health records.96 
A second difference is that RMATs that are approved under the 
accelerated pathway are subject to postapproval requirements and 
may meet such obligations “as appropriate” by submitting clinical 
evidence, clinical studies, patient registries, or “other sources of real 
world evidence, such as electronic health records”; by collecting 
larger confirmatory data sets; or by monitoring patients treated with 
the therapy prior to its approval.97 This is a larger category of 
postapproval options than is available under the Accelerated 
Approval pathway, where the sole postapproval requirement option is 
that the “sponsor conduct appropriate postapproval studies to verify 
and describe the predicted effect on irreversible morbidity or 
mortality or other clinical benefit.”98 
FDA officials have acknowledged both the benefits and limitations 
of using real world evidence. In a 2016 New England Journal of 
Medicine article authored by fifteen top FDA officials, the officials 
observed that the definition of “real world evidence” encompasses 
data from randomized trials conducted in a real-world setting, so 
viewing “real-world evidence” and “randomized trials” as mutually 
exclusive is incorrect.99 But concerns about the quality of real world 
evidence, and the limitations of current analytical approaches, 
suggest limits to the value of such data.100 The quality of real world 
                                                                                                                 
 95. Id. § 356(g)(6)(B)(ii). 
 96. See Zachary Brennan, Real World Evidence: FDA Commits to Advancing Its Use, RAPS (Sept. 
19, 2017), http://www.raps.org/Regulatory-Focus/News/2017/09/19/28491/Real-World-Evidence-FDA-
Commits-to-Advancing-its-Use/ [https://perma.cc/K7FX-9KB9] (describing FDA Commissioner Scott 
Gottlieb’s remarks to the National Academy of Sciences’ workshop on incentivizing providers to enter 
data into electronic medical records at the point of care). 
 97. 21 U.S.C. § 356(g)(7)(A–C). 
 98. Id. § 356(c)(2)(A). 
 99. Rachel E. Sherman et al., Real-World Evidence—What Is It and What Can It Tell Us, 357 NEW 
ENG. J. MED. 2293, 2293, 2295 (2016) (referencing the Salk field trial of the polio vaccine). 
 100. Id. 
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evidence may be less robust than that collected in randomized 
clinical trials because real world evidence is not subject to the same 
rigorous quality requirements, like the use of eligibility criteria, 
detailed case reporting forms, and intensive monitoring.101 Rather, its 
collection is often not for the purpose of supporting research, and is 
likely not optimized or organized for research purposes.102 
Stakeholders are developing methods to incorporate real world 
evidence into research, and efforts are ongoing.103 Current 
limitations, however, are particularly evident when real world 
evidence is intended to support the effectiveness of a product and the 
expected or observed effect is relatively small.104 
The RMAT approval pathway is only available to those products 
that meet the eligibility requirements by intending to treat serious or 
life-threatening diseases or conditions and filling an unmet medical 
need.105 This reflects a policy judgment that patients with serious or 
life-threatening diseases without access to treatment should be 
permitted to trade certainty for earlier access. 
II.   Defenses and Critiques of Existing Regulation 
Critics charge the FDA with over-regulating regenerative medicine 
therapies.106 They point to patients with serious illnesses for whom a 
delay in product approval may prove fatal.107 At the extreme, some 
stakeholders argue that regenerative medicine therapies, or at least 
significant subsets, should not be regulated at all. For example, in 
U.S. v. Regenerative Sciences, the defendant unsuccessfully argued to 
the District of Columbia Circuit Court that the regenerative medicine 
product at issue was not a drug, biological product, or tissue product, 
but rather the practice of medicine.108 Because this case and its 
                                                                                                                 
 101. Id. at 2293. 
 102. Sherman et al., supra note 99, at 2294. 
 103. Id. 
 104. Id. at 2295. 
 105. 21 U.S.C. § 356(g)(2)(B)–(C). 
 106. See, e.g., Riley, supra note 17, at 465; c.f., Margaret Hamburg, M.D. & Joshua M. Sharfstein, 
M.D., The FDA as a Public Health Agency, 360 NEW ENG. J. MED. 2493, 2493 (2009). 
 107. See Hamburg & Sharfstien, supra note 106, at 2493. 
 108. United States v. Regenerative Sciences, LLC, 741 F.3d 1314, 1319 (D.C. Cir. 2014). 
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implications have been thoroughly analyzed elsewhere,109 I will not 
restate the issues, but the court was right to deny the defendant’s 
argument, for both legal and normative reasons. Fundamentally, 
regulation of regenerative medicine therapies is important to protect 
the public health and to encourage data generation that advances 
scientific understanding of the field. 
A.   Why Regulation is Important 
The goal of public health is to “fulfill . . . society’s interests in 
assuring the conditions in which people can be healthy.”110 As a 
public health agency, the FDA supports the goal of assuring healthy 
conditions not only by ensuring the safety, efficacy, and security of 
medical products like drugs, devices, and biologics, but also by 
“helping to speed innovations that make medical products more 
effective, safer, and more affordable and by helping the public get the 
accurate, science-based information they need to use medical 
products.”111 
To ensure the safety, efficacy, and security of new products, the 
FDA seeks to reduce harms before they occur by acting as a 
gatekeeper to the marketplace for new biologics and drugs.112 To do 
this, the FDA evaluates evidence of a product’s safety and efficacy 
submitted by the product sponsor, and balances the potential benefits 
that a therapy can provide with its potential harms.113 When 
                                                                                                                 
 109. See, e.g., Mary Ann Chirba & Stephanie Garfield, FDA Oversight of Autologous Stem Cell 
Therapies: Legitimate Regulation of Drugs and Devices or Groundless Intervention with the Practice of 
Medicine?, 7 J. HEALTH & BIOMEDICAL L. 233, 253, 271 (2011); Greg Pivarnik, Cells as Drugs? 
Regulating the Future of Medicine, 40 AM. J. L. & MED. 298, 319 (2014); Barbara von Tigerstrom, The 
Food and Drug Administration, Regenerative Sciences, and the Regulation of Autologous Stem Cell 
Therapies, 66 FOOD & DRUG L.J. 479, 504 (2011). 
 110. Hamburg & Sharfstein, supra note 106, at 2493 (providing the Institute of Health’s definition of 
“public health”). 
 111. U.S. FOOD & DRUG ADMIN., What We Do, https://www.fda.gov/aboutfda/whatwedo/ 
[https://perma.cc/5C7J-5PGK] (last updated Dec. 29, 2017). 
 112. See Sidney Shapiro & Robert L. Glicksman, RISK REGULATION AT RISK: RESTORING A 
PRAGMATIC APPROACH 6 (2003) (quoting John Applegate, The Perils of Unreasonable Risk: 
Information, Regulatory Policy, and Toxic Substances Control, 91 COLUM. L. REV. 261, 273 (1991)) 
(“Regulation based on risk permits regulatory action based on ex ante collective danger rather than ex 
post individual injury, and also operates preventively to avert injury to the public as a whole.”). 
 113. Hamburg & Sharfstein, supra note 106, at 2492. 
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determining whether to approve a product, the agency considers the 
severity of the targeted disease or condition, whether alternative 
treatments are available, and the level of knowledge about patient 
responses to the therapy.114 
This gatekeeping function is vital for patient protection because a 
patient, by herself, has inadequate information to determine whether 
a drug or biologic is safe and effective even after receiving it.115 
Although the patient can certainly identify whether she feels better or 
worse after receiving a drug or biologic intervention, factors other 
than the therapy may cause some or all of the change in her 
wellbeing.116 Because of this inability to judge the therapy even after 
experiencing it, the patient must rely on the expertise of her doctor 
both to determine her need for treatment and to choose the correct 
medical treatment.117 A dishonest doctor could exploit the patient’s 
lack of information by recommending a product or treatment that is 
unnecessary, ineffective, harmful, or more expensive than other 
options.118 Regulations that reduce this information asymmetry by 
demanding that products demonstrate safety and effectiveness before 
entering the marketplace help protect patients against receiving 
unsafe or ineffective treatments. 
The FDA’s role in public health is not limited to approving or 
denying applications for premarket approval. It has another mission, 
                                                                                                                 
 114. Id. 
 115. STEPHEN BREYER, REGULATION AND ITS REFORM 28 (1982); W. Nicholson Price II, Regulating 
Black-Box Medicine, 116 MICH. L. REV. 421, 461–65 (2017); Michael R. Darby & Edi Karni, Free 
Competition and the Optimal Amount of Fraud, 16 J. L. & ECON. 67, 81 (1973) (introducing the concept 
of credence goods). 
 116. This is, of course, the reason that randomized, controlled trials remain the gold-standard in 
determining the safety and efficacy of new treatments. See, e.g., Bonnie Sibbald & Martin Roland, 
Understanding Controlled Trials: Why Are Randomised Trials Important?, 316 BRIT. MED. J. 201, 201 
(1998). 
 117. See, e.g., Uwe Dulleck & Rudolf Kerschbamer, On Doctors, Mechanics, and Computer 
Specialists: The Economics of Credence Goods, 44 J. ECON. LIT. 5, 6 (2006). 
 118. Dulleck and Kerschbamer provide specific examples that demonstrate that information 
asymmetry matters in medical decision-making. A 1997 Swiss study reported that the average person’s 
likelihood of receiving one of seven major surgeries was one-third greater than that of a physician or a 
physician’s family member. See id. at 6 (citing Winand Emons, Credence Goods and Fraudulent 
Experts, 28 RAND J. ECON. 107 (1997)). A Federal Trade Commission study revealed the tendency of 
optometrists to prescribe unnecessary treatments. See id. at 6 (citing Asher Wolinsky, Competition in a 
Market for Informed Experts’ Services, 24 RAND J. ECON. 380 (1993)). 
20
Georgia State University Law Review, Vol. 34, Iss. 3 [2018], Art. 3
https://readingroom.law.gsu.edu/gsulr/vol34/iss3/3
2018] REFORMING REGENERATIVE MEDICINE REGULATION 651 
to promote innovation that makes drugs and biologics safer, more 
effective, and more affordable.119 And it uses its gatekeeper 
requirements for this purpose as well. By requiring private firms to 
submit clinical trial evidence for premarket approval, the FDA 
incentivizes those firms to create valuable data on the risks and 
benefits of medical products.120 This information is used not only to 
advise doctors and patients,121 but also to further scientific 
understanding of how the medical product acts within the human 
body.122 This understanding enhances biomedical knowledge, and 
researchers and firms can use it to increase the efficiency of research 
and development of new potential therapies.123 
Regenerative medicine therapies are appropriate subjects for pre-
market regulation both to protect patients and to promote innovation. 
Harms from unsafe or ineffective regenerative medicine treatments 
can manifest as economic, physical, or opportunity cost harms. 
Additionally, data from clinical trials can advance the state of 
understanding of how regenerative medicines affect the human body. 
1.   Economic Harms 
Economic harm occurs when a patient spends money on a therapy 
that does not provide the benefits promised by its marketing or 
advertising claims.124 This was the underlying claim in a putative 
class action lawsuit against Stemgenex Medical Group, Inc., a stem 
cell clinic in southern California.125 The five named plaintiffs 
                                                                                                                 
 119. Eisenberg, supra note 76, at 370. 
 120. Id. 
 121. See, e.g., Wash. Legal Found. v. Friedman, 13 F. Supp. 2d 51, 69 (D.D.C. 1998) (dismissed on 
appeal as moot) (upholding substantial government interest in ensuring that physicians receive accurate 
and unbiased information so that they make informed prescription choices); Eisenberg, supra note 76, at 
374 (“The doctors who prescribe drugs are the principle targets of information dissemination by 
pharmaceutical firms, although in recent years pharmaceutical firms have increasingly advertised their 
products directly to patients.”). 
 122. Daria Kim, Knowledge Sharing as a Social Dilemma in Pharmaceutical Innovation, 71 FOOD & 
DRUG L.J. 673, 691–92 (2016). 
 123. Id. 
 124. See, e.g., Dulleck & Kerschbamer, supra note 117, at 6. 
 125. Fourth Amended Complaint at 2, Moorer v. Stemgenex Med. Grp., Inc., No. 3:16-cv-02816-
AJB-NLS, 2017 WL 3992747(S.D. Cal. May 18, 2017); see also Michael Hiltzik, The Stem Cell 
Therapies Offered by this La Jolla Clinic Aren’t FDA Approved, May Not Work—and Cost $15,000, 
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suffered from various conditions, including lupus, diabetes, a 
“painful condition affecting [plaintiff’s] spine and joints,” and 
multiple sclerosis.126 They alleged that, because of the stem cell 
clinic’s marketing claims, they spent $14,900 per treatment on stem 
cell therapy that had no beneficial effect.127 Similarly, a separate 
lawsuit against the Lung Institute, a Florida-based stem cell clinic, 
alleged that the clinic promised that its stem cell therapies would 
treat lung disease, charged the plaintiff $7,500 for the initial 
treatment, and then blamed her for the treatment’s ineffectiveness 
because she could not afford monthly “reboost” shots costing an 
additional $70 per month.128 Instead of benefiting the patients’ 
wellbeing, these expensive treatments caused them economic harms. 
2.   Physical Harms 
Even more troubling are the direct physical harms that patients 
may suffer from regenerative medicine therapies. Physical harms 
have occurred in both clinical trial settings and in unregulated stem 
cell clinics. Harms in some regenerative medicine trials have been 
well-publicized. For example, two patients’ deaths in a 2016 gene 
editing cancer treatment trial caused the FDA to halt the trial.129 
Unregulated treatments from stem cells clinics have also caused 
significant physical harms. Two separate lawsuits filed by patients 
against a Florida stem cell clinic alleged that the clinic directly 
injected a purported stem cell therapy into their eyes as treatment for 
macular degeneration.130 As a result, the plaintiffs alleged that they 
                                                                                                                 
L.A. TIMES (Mar. 31, 2017, 1:50 PM), http://www.latimes.com/business/hiltzik/la-fi-hiltzik-stemgenex-
20170330-story.html [https://perma.cc/G2SU-2AB7]. 
 126. Fourth Amended Complaint, supra note 125, at 3–5. 
 127. Id. at 5. The Fourth Amended Complaint incorporates screen shots from StemGenex’s website 
that touts “stem cell therapy studies” for autoimmune diseases, diabetes, multiple sclerosis, and 
osteoarthritis and rheumatoid arthritis, among other conditions. Id. at 11–14. 
 128. Complaint at 4, Rivero v. Lung Institute, LLC, No. 45360019 (Fla. Cir. Ct. Aug. 14, 2016); see 
also Tony Marrero, Unsatisfied Former Patient Files Class-Action Lawsuit Against Lung Institute, 
TAMPA BAY TIMES (Aug. 26, 2016, 1:27 AM), http://www.tampabay.com/news/courts/civil/unsatisfied-
former-patient-files-class-action-lawsuit-against-lung/2290989 [https://perma.cc/H3FM-R76S]. 
 129. Damian Garde & Meghana Keshavan, Two Patient Deaths Halt Trial of Juno’s New Approach to 
Treating Cancer, STAT (Nov. 23, 2016), https://www.statnews.com/2016/11/23/juno-cancer-
immunotherapy-deaths-2/ [https://perma.cc/Y4LM-8RDW]. 
 130. Amended Complaint for Damages and Demand for Jury Trial at 1, Bade v. Greenbaum, No.: 
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suffered permanent damage, including blindness.131 Another patient, 
a sixty-six-year-old man who sought treatment for lingering effects 
from an ischemic stroke, received multiple stem cell injections, 
described as mesenchymal, embryonic, and fetal neural, at several 
clinics outside the United States.132 He developed a massive lesion 
growing around his spinal cord; a biopsy revealed that the cells were 
not from his body. He developed lower back pain, paraplegia, and 
urinary incontinence.133 In another example, a boy who received fetal 
stem cell transplants at age nine developed abnormal growths in his 
brain and spinal cord.134 Researchers discovered that the brain tumor 
contained cells from two or more donors, at least one of whom was 
female, suggesting that the stem cells caused the tumor.135 
3.   Opportunity Cost Harms 
Patients who receive regenerative medicine therapies may forego 
conventional treatment options that are more effective, less harmful, 
or less expensive. By choosing an inferior regenerative medicine 
therapy instead of a different, superior therapy, a patient suffers not 
only economic or physical harms wrought by the therapy, but also the 
lost value that she would have received from the superior therapy. It 
is hard to quantify this risk. In one sense, because many developing 
regenerative medicine therapies are intended to treat or mitigate the 
effects of diseases or conditions that have no current effective 
                                                                                                                 
2015-021463 CA 30 (Fla. Cir. Ct. July 19, 2016) [hereinafter Bade Complaint]; Complaint at 2, Noble 
v. U.S. Stem Cell, Inc., No: CACE-15-021101 (04) (Fla. Cir. Ct. Nov. 30, 2015) [hereinafter Noble 
Complaint]. 
 131. The Bade complaint specifically alleges that the plaintiffs suffered permanent blindness. Bade 
Complaint, supra note 130, at 1. The Noble complaint did not specifically allege this fact; both 
complaints listed identical damages. See id. at 11; Noble Complaint, supra note 130, at 16 (noting that 
alleged damages include “bodily injury; pain and suffering; disability; disfigurement; loss of the 
capacity for the enjoyment of life; aggravation of pre-existing conditions; medical and hospital care and 
expenses; loss of earnings; loss of earning capacity in the future; rehabilitation expenses; and mental 
distress”). 
 132. U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCES RELATING TO THE REGULATION OF HUMAN 
CELLS, TISSUES, OR CELLULAR OR TISSUE-BASED PRODUCTS 106 (Sept. 12, 2016). 
 133. Id. 
 134. Ninette Amariglio et al., Donor-Derived Brain Tumor Following Neural Stem Cell 
Transplantation in an Ataxia Telangiectasia Patient, 6 PLOS MEDICINE 221, 223 (2009). 
 135. Id. at 255–26. 
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treatment, the potential for opportunity cost harms may be relatively 
small. But past experience demonstrates that opportunity cost harms 
are not merely theoretical, and will likely increase as additional 
regenerative medicine therapies become available.136 
History provides us with a compelling example of opportunity 
cost. Between 1985 and 1998, over 30,000 women in the United 
States with breast cancer received high-dose chemotherapy plus 
autologous bone marrow transplants instead of the standard-dose 
treatments for breast cancer.137 Early observations of tumor shrinkage 
in the 1980s, followed by Phase 2 clinical trials reporting improved 
survival rates, excited researchers and patients.138 Although the 
treatment was expensive at $80,000,139 and “very toxic,”140 the 
combined forces of patients’ hopes, powerful lobbying efforts, 
oncology researchers, and media coverage drove the adoption of this 
novel therapy.141 But more critical inquiries in the early 1990s noted 
methodological shortcomings in the Phase 2 trials, particularly 
selection bias.142 As additional Phase 2 and Phase 3 trial results were 
published in the late 1990s that indicated high-dose chemotherapy 
plus autologous bone marrow transplants did not increase the 
patients’ survival rates, enthusiasm for the treatment plummeted.143 
But those patients who received the treatment forewent the 
opportunity to receive conventional breast cancer treatment that 
involved decidedly fewer side effects. Instead, these patients’ choice 
of the novel treatment exposed them to risks of acute-onset toxicities, 
                                                                                                                 
 136. See Michelle M. Mello & Troyen A. Brennan, The Controversy Over High-Dose Chemotherapy 
with Autologous Bone Marrow Transplant for Breast Cancer, 20 HEALTH AFFAIRS 101, 101 (2001). 
 137. Daniel F. Hayes, False Hope: Bone Marrow Transplantation for Breast Cancer, 357 N. ENGL. J. 
MED. 1059, 1059 (2007) (book review); see also Mello & Brennan, supra note 136, at 110 (estimating 
that 42,680 autologous bone marrow transfers were performed on breast cancer patients between 1990 
and 1999). 
 138. Mello & Brennan, supra note 136, at 103. 
 139. Id. at 102. 
 140. Id. (quoting Position Statement, Am. Soc’y of Clinical Oncology, High-Dose Chemotherapy 
with Bone Marrow Transplant for Breast Cancer Patients, (Mar. 2000) (on file with author)). 
 141. Id. at 106–07. 
 142. Id. at 103. 
 143. Id. For one significant study demonstrating no benefit, see S. Rodenhuis et al., Randomised Trial 
of High-Dose Chemotherapy and Haemopoietic Progenitor-Cell Support in Operable Breast Cancer 
with Extensive Axillary Lymph-Node Involvement, 352 LANCET 515 (1998). 
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such as sepsis and pulmonary failure, and, among others, leukemia, 
bone marrow insufficiency, psychosexual disorders, increased 
vulnerability to infection, and even death.144 
4.   Furthering Scientific Understanding 
Requiring clinical trials to demonstrate safety and efficacy can also 
further the field of regenerative medicine. Cells are extraordinarily 
complex, which makes predicting their behavior in a new 
environment challenging.145 Clinical trial data can further the science 
of regenerative medicine. Publication of clinical trial results can 
“promote transparency in the clinical translation of stem cell-based 
therapies, . . . ensure development of clinically effective and 
competitive stem cell-based therapies, . . . prevent individuals in 
future clinical trials from being subjected to unnecessary risk, 
and . . . respect research subjects’ contribution.”146 As former FDA 
officials cautioned, “[W]e must first understand [a regenerative 
medicine therapy’s] risks and benefits and develop therapeutic 
approaches based on sound science. Without a commitment to the 
principles of adequate evidence generation that have led to so much 
medical progress, we may never see stem-cell therapy reach its full 
potential.”147 
B.   Stakeholder Critiques 
At a public hearing in September 2016, the FDA solicited 
feedback from stakeholders on the regulation of regenerative 
medicine therapies.148 Participants raised many specific issues, but 
two arose time and again: the regulation of allografts (tissue 
                                                                                                                 
 144. Mello & Brennan, supra 136, at 110–11. 
 145. Peter W. Marks, Celia M. Witten & Robert M. Califf, Clarifying Stem-Cell Therapy’s Benefits 
and Risks, 376 NEW ENG. J. MED. 1007, 1008 (2017). 
 146. INT’L SOC’Y FOR STEM CELL RESEARCH, GUIDELINES FOR STEM CELL RESEARCH AND CLINICAL 
TRANSLATION 24 (2016). 
 147. Marks et al., supra note 145, at 1007. 
 148. See, e.g., Riley, supra note 17, at 458; c.f., Hamburg & Sharfstein, supra note 106, at 2493 
(stating that “the ultimate measures of the FDA’s success should reflect its fundamental goals and go 
beyond such intermediate measures as the number of facilities inspected or drugs approved”). 
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transplants from one person to another) and the regulation of 
unapproved stem cell therapies.149 On both issues, some stakeholders 
argued for less robust regulation while others defended the existing 
structure and argued for stronger enforcement of the existing 
regulations.150 
Regulatory economist Bruce Yandle observed that interest groups 
are more powerful when two factions join together: the 
economically-motivated, and those providing a moral justification for 
the same regulatory policy.151 His colorful name for this theory, 
“Bootleggers and Baptists,” derives from two distinct groups’ 
support for a law that required liquor stores to close on Sundays. The 
Baptists supported the law for religious purposes, while the 
bootleggers supported the law because the absence of competition 
once a week increased demand for their product. The coalition of 
Baptists and bootleggers made it easier for politicians to favor both 
groups–they could present themselves as being motivated by the 
public interest, while benefitting from the financial support of the 
bootleggers.152 Scholars have observed the persuasive power of 
similar alliances across a number of regulatory settings.153 The 
coalition of stakeholder interests in regenerative medicine provides 
another such example. 
First, consider allografts. Some stakeholders advocated for a looser 
interpretation of the section 361 requirements so that their products 
would qualify as section 361 products and fall under the intermediate 
regulatory tier instead of the more stringent biologics tier.154 But in 
                                                                                                                 
 149. U.S. FOOD & DRUG ADMIN., CTR. FOR BIOLOGICS EVALUATION AND RESEARCH, PART 15 
HEARING: DRAFT GUIDANCES RELATING TO THE REGULATION OF HUMAN CELLS, TISSUES, OR 
CELLULAR OR TISSUE-BASED PRODUCTS 29 (Sept. 12, 2016) [hereinafter CBER HCT/Ps Hearing, Sept. 
12, 2016]. 
 150. Id. 
 151. ADAM SMITH & BRUCE YANDLE, BOOTLEGGERS & BAPTISTS: HOW ECONOMIC FORCES AND 
MORAL PERSUASION INTERACT TO SHAPE REGULATORY POLITICS at viii (2014). 
 152. Id. 
 153. Id.; see also Jonathan H. Adler et al., Baptists, Bootleggers & Electronic Cigarettes, 33 YALE J. 
ON REG. 313 (2016). 
 154. See, e.g., CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 20–21 (statement of Pamela 
Vetter, director of regulatory policy at Allosource, a nonprofit cellular and tissue network, arguing for 
broader definitions of “original relevant characteristics” and “main function”); id. at 71 (statement of Dr. 
Justin Deurling, RTI Surgical, a manufacturer and distributor of HCT/Ps, arguing for a broader reading 
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response, an alliance of financial and moral interests defended the 
existing requirements for premarket approval. Representing financial 
interests were those firms that manufacture products subject to the 
highest tier of FDA regulation. For example, at the hearing, the 
company that makes Apligraf, an FDA-approved product, argued that 
competitive products should be required to obtain premarket 
approval.155 Representing the moral interest were healthcare 
providers who warned the FDA that patients’ health may be put at 
risk when allograft products are marketed without FDA approval 
because healthcare providers may unknowingly use an allograft that 
has not undergone the clinical trials required for FDA approval.156 
Dr. Scott James, a vascular surgeon at Beth Israel Deaconess 
Plymouth Hospital explained, “The patients that we see in our 
practice have devastating conditions and the consequences of using 
treatments that are not backed by rigorous science can be disastrous. 
Our patients deserve to know that the therapies we give them have 
been proven to be both safe and effective.”157 
Similar alliances arose around unapproved stem cell treatments 
with Baptists and bootleggers on both sides. Stakeholders who claim 
that the FDA overregulates stem cells point to the FDA’s approval of 
a single class of stem cell products as evidence that the FDA moves 
too slowly.158 Industry representatives, who would benefit financially 
from lighter regulation, argued that autologous stem cell therapies 
should not be regulated, and raised concerns of federalism and 
patient autonomy.159 Patients and their advocates lent moral credence 
                                                                                                                 
of “minimal manipulation” to cover certain sterilization and decellularization techniques). 
 155. Id. at 67. 
 156. See, e.g., U.S. FOOD & DRUG ADMIN. CTR. FOR BIOLOGICS EVALUATION AND RESEARCH, PART 
15 HEARING: DRAFT GUIDANCES RELATING TO THE REGULATION OF HUMAN CELLS, TISSUES, OR 
CELLULAR OR TISSUE-BASED PRODUCTS 96 (Sept. 13, 2016) [hereinafter CBER HCT/Ps Hearing, Sept. 
13, 2016] (statement of Dr. Harold Brem, Surgeon and Professor of Surgery at Stony Brook University 
School of Medicine); id. at 132 (statement of Marie Louise Gehling, N.P.); id. at 181 (statement of 
Sheila Sabon DeCastro, N.P. at Mass General Hospital and a consulting director to the tissue program at 
Beth Israel Deaconness Hospital Plymouth). 
 157. Id. at 149. 
 158. Alexey Bersnenev, Is FDA Slowing Down the Progress in Clinical Cell Therapy?, STEM CELL 
ASSAYS (Nov. 27, 2011), http://stemcellassays.com/2011/11/fda-slowing-progress-cell-therapy/ 
[https://perma.cc/8RFV-X774]. 
 159. See, e.g., CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 81–82 (statement of Kristin 
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to these claims. One patient suffering from rheumatoid arthritis 
obtained an unapproved adipose-derived treatment from a stem cell 
clinic in California and credited the treatment with her remission.160 
Another patient suffering from juvenile idiopathic arthritis credited 
an unapproved adipose–derived treatment with drastically improving 
her quality of life.161 Still another credited a similar treatment with 
alleviating her multiple sclerosis symptoms.162 
But other stakeholders argued for increased enforcement of 
existing regulations, and included health care providers and 
representatives of competing products regulated as biologics.163 Not 
only do unapproved stem cell treatments lack scientific evidence of 
efficacy,164 they argued, but patients also have insufficient 
information to understand the treatments165 and may suffer physical 
harm.166 
                                                                                                                 
Comella, U.S. Stem Cell); id. at 151 (statement of Dr. Elliott Lander, Cell Surgical Network); id. at 153 
(statement of Michael Badowski, AdiCyte). A significant point, oft repeated, was the claim that the 
treatments offered by stem cells clinics are like surgery, and thus should be included in the same 
surgical procedure exception. Id. The second major argument was that of patient autonomy: “Patients 
have a right to provide informed consent decision about how they’re going to use these treatments 
themselves. They have a right to alternative therapies.” Id. at 85. Another similar argument was raised: 
“Why would the FDA regulate our own body tissue and consider this a drug?” Id. at 83. 
 160. See CBER HCT/Ps Hearing, Sept. 13, 2016, supra note 156, at 109–10 (statement of Georgianna 
Crocker). 
 161. See id. at 142–43 (statement of Sarah Hughes). 
 162. See id. at 168–70 (statement of Kristin Marr). 
 163. See, e.g., CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 44–45 (statement of Dr. 
Eric Daniels). Even these competing manufacturers couched their advocacy in publicly-interested 
terminology. Consider the statements of Dr. Eric Daniels, the chief medical officer of Kerastem 
Technologies, which sponsors a Phase 2 trial investigating the role of adipose and its derivative stromal 
vascular fraction for genetic alopecia. Dr. Daniels warned that after a decade and a half of cell therapies, 
“we still lack certainty around critical issues of identity, purity, and dose response.” Id. at 44–45. He 
continued, “Ad hoc manufacturing in an operating room, using unregulated systems and tools and/or 
processes, as well as negligent promotion will not help uncover and, more importantly, broadly 
disseminate the therapeutic potential—in this case of adipose-derived therapies. This will only come 
from a series of focused, well-designed, and controlled clinical trials.” Id. 
 164. See CBER HCT/Ps Hearing, Sept. 13, 2016, supra note 156, at 156 (Jeanne Loring, stem cell 
researcher at the Scripps Research Institute, stated, “Adipose cell therapy is governed by that overused 
axiom, if the only tool you have is a hammer, you will treat everything as if it is a nail. It isn’t logical or 
scientific to assume that all disorders can be treated with a single type of cell.”) 
 165. See CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 97 (statement of Dr. Steve Bauer, 
FDA, reviewing September 8,, 2016, workshop of Scientific Evidence in development of HCT/P 
products that are subject to premarket approval). On the concern that stem cell clinics may untruthfully 
or confusingly allege that the therapies are part of a clinical trial subject to IRB approval, see Paul 
Knoepfler, Does Stem Cell Clinic IRB Approval Mean Much? Insights from Blinding Cases, NICHE 
(Mar. 23, 2017), https://ipscell.com/2017/03/does-stem-cell-clinic-irb-approval-mean-much-insights-
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The Bootleggers and Baptists theory suggests the use of financial 
incentives to sway a policymaker’s support. And although it is nearly 
impossible to link financial contributions directly to policymaker 
action, it is worth noting that the regenerative medicine arena is 
subject to the same lobbying influences as many other areas. For 
example, MiMedx, a for-profit company that sells regenerative 
products created from amniotic tissue, received an untitled letter from 
the FDA in 2013 asserting that the company’s product failed to 
receive the proper premarket approval. In 2016, MiMedx contributed 
ten thousand dollars to the campaign of the senator who introduced 
the REGROW Act, the reform bill discussed in the next section.167 
III.   Reform of Section 351 Products 
Building on the criticism that the FDA’s regulation of regenerative 
medicine products is overinclusive and too slow, reform advocates 
have pushed for speedier FDA review in the form of adaptive 
licensing. Under this proposed framework the FDA would approve a 
product based on less-than-standard clinical evidence of efficacy and 
safety, and would restrict patient access to the product while the 
sponsor gathers postmarket evidence of the product’s effect in a real 
world setting. Then, based on the evidence continuously gathered, the 
FDA could withdraw the product’s initial approval, adjust marketing 
restrictions, or lift the restrictions altogether. 168 
While adaptive licensing offers the benefits of early market access 
and the continued generation of evidence of a product’s safety and 
effectiveness (or purity and potency), a closer analysis reveals 
                                                                                                                 
from-blinding-case/ [https://perma.cc/7SPV-XBUG]. 
 166. CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 105–06. 
 167. Paul Knoepfler, REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises, 
NICHE (Nov. 3, 2016), https://ipscell.com/2016/11/regrow-act-mark-kirk-lobbying-contributions-yield-
stem-cell-surprises/ [https://perma.cc/6VNL-JLHC]; Candidate Information for Mark Kirk, FED. 
ELECTION COMM’N, https://classic.fec.gov/finance/disclosure/candcmte_info.shtml 
[https://perma.cc/RH3V-DKEM] (last visited Mar. 5, 2018) (searching “Mark Kirk” in the “partial 
name” field). Astellas Pharma, a Japanese pharma company involved in stem cell research, also made a 
contribution to Kirk’s campaign. Id. 
 168. Shannon Gibson & Trudo Lemmens, Niche Markets and Evidence Assessment in Transition: A 
Critical Review of Proposed Drug Reforms, 22 MED. L. REV. 200, 208 (2014). This is called “adaptive 
licensing.” Id. 
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fundamental flaws. Not only would it require Congress to grant new 
authority to the FDA, but the risk of harm to patients and practical 
barriers to industry participation make such a framework unworkable 
and unwise. A structural overhaul of the premarket approval system 
would be expensive, and evidence suggests that regulatory science is 
not yet able to accurately predict when the potential benefits of early 
access outweigh the risks of harm. 
This section outlines three proposals for adaptive licensing. By 
evaluating the proposals using a theory of adaptive regulation, I 
conclude that implementing an adaptive licensing scheme does not 
offer sufficient benefits to outweigh the risks and burdens. 
A.   Adaptive Licensing 
Adaptive licensing reform proposals reached a zenith in the 
REGROW Act, which was introduced in 2015 but ultimately died 
without a vote.169 It did, however, set the stage for the inclusion of 
RMAT provisions in the 21st Century Cures Act, which passed the 
following year.170 The REGROW Act arose from the proposals that 
preceded it: Arnold Caplan co-authored the initial proposal, then 
served as an “expert panelist” with the Bipartisan Policy Center 
during its promulgation of the second proposal.171 Mark Kirk, the 
politician who introduced the third proposal, the REGROW Act, 
specifically credited the Bipartisan Policy Center report when he 
introduced his bill. 172 
                                                                                                                 
 169. See S. 2689 – REGROW Act, CONGRESS.GOV, https://www.congress.gov/bill/114th-
congress/senate-bill/2689 [https://perma.cc/FV4G-4QAE] (last visited Jan. 14, 2018). 
 170. 21st Century Cures Act, sec. 3033, 130 Stat. 1101 (2016) (codified at 21 U.S.C. § 356). 
 171. Michael Eisenstein, Regulation: Rewriting the Regenerative Rulebook, 540 NATURE S65, S66 
(2016) (“Caplan helped formulate the REGROW Act.”), https://www.nature.com/articles/540S63a.pdf 
[https://perma.cc/KAD4-SR3T]. 
 172. Press Release, Office of Senator Mark Kirk, REGROW Act Accelerates New Therapies to Help 
Patients Living with Disease; Stem Cell Therapies Help Alzheimer’s, Parkinson’s, Sickle Cell Patients 
(Mar. 16, 2016) (on file with author); see also Cade Hildreth, Kirk, Manchin, Collins Introduce Bill to 
Speed Development of Regenerative Medicine, BIOINFORMANT (Mar. 16, 2016), 
https://www.bioinformant.com/kirk-manchin-collins-introduce-bill-to-speed-development-of-
regenerative-medicine/#more-5609 [http://perma.cc/GVY5-4JRZ]. 
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1.   Describing Adaptive Licensing 
Adaptive licensing exemplifies a lifecycle approach to medical 
product evaluation where market access for drugs is progressive.173 
The model diverges from the traditional approval model where a drug 
transitions from experimental to approved in a single moment, and 
grows from the principle that there is no “magic moment” when 
regulators can conclusively determine that a drug is safe and 
effective.174 Adaptive licensing frameworks envision two (or more) 
stages in a licensing pathway.175 In the first stage, a drug receives an 
initial license based on less rigorous evidence than the two Phase 3 
randomized controlled trials typically required for approval.176 The 
initial patient population is restricted; the particular restrictions 
depend on the product’s particular issues and the level of knowledge 
about the product’s use.177 In the second stage, after the initial license 
is granted, the sponsor continues to generate evidence on the drug’s 
use.178 This evidence could “encompass the full methodology 
spectrum, including randomly-controlled clinical trials (RCTs), 
pragmatic clinical trials, clustered RCTs, observational studies based 
on electronic medical records, registries, and other forms of active 
and passive surveillance.”179 Access expands, or the drug is 
withdrawn, as the sponsor reports additional postmarket evidence of 
safety and effectiveness.180 
                                                                                                                 
 173. See, e.g., Gibson & Lemmens, supra note 168, at 208; W. Nicholson Price II & Arti K. Rai, 
Manufacturing Barriers to Biologics Competition and Innovation, 101 IOWA L. REV. 1023, 1061 
(2016); Anna B. Laakmann, Collapsing the Distinction Between Experimentation and Treatment in the 
Regulation of New Drugs, 62 ALA. L. REV. 305, 332 (2011) (discussing adaptive licensing for new 
drugs). W. Nicholson Price II, supra note 115, at 461–65 (discussing adaptive licensing for medical 
algorithms). 
 174. Eichler, supra note 77, at 427; see also Laakmann, supra note 173, at 308. 
 175. Eichler, supra note 77, at 430. 
 176. INST. OF MED. (US) COMM. OF ACCELERATING RARE DISEASE RESEARCH & ORPHAN PROD. 
DEV., RARE DISEASES AND ORPHAN PRODUCTS: ACCELERATING RESEARCH AND DEVELOPMENT 155 
(Marilyn J. Field & Thomas F. Boat eds., 2010). 
 177. Arnold I. Caplan & Michael D. West, Progressive Approval: A Proposal for a New Regulatory 
Pathway for Regenerative Medicine, 3 STEM CELLS TRANSLATIONAL MED. 560, 562 (2014); Eichler, 
supra note 77, at 430. 
 178. Caplan & West, supra note 177, at 561. 
 179. Eichler, supra note 77, at 429. 
 180. Id. at 431; Caplan & West, supra note 177, at 561. 
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Depending on the risk factors of the product, the path to approval 
would vary for each therapy.181 Just as the current system’s 
accelerated approval pathway acknowledges that patients, 
practitioners, and regulators are willing to trade greater unknowns 
about safety and effectiveness to enable access for patients facing 
life-threatening or serious conditions with a lack of treatment options, 
an adaptive licensing framework would expect that other trade-offs 
between certainty and access might be acceptable in scenarios less 
extreme than those that already qualify for accelerated approval.182 
Three proposals suggest variations on the theme of adaptive 
licensing for regenerative medicines, but differ in important aspects. 
First, they differ as to which therapies qualify. Under the Caplan and 
West proposal, only those therapies that offer an advantage in 
treating serious diseases are eligible for adaptive licensing, whereas 
the other two restrict eligibility to certain lower-risk therapies. 
Second, they differ as to the evidence required for approval. The 
Caplan and West proposal demands only pretrial and Phase 1 studies, 
while the other two require both Phase 1 and Phase 2 trials. Third, 
they vary on postmarketing controls. The Caplan and West proposal 
suggests the use of significant controls to slow product diffusion into 
the marketplace, while the other two suggest no controls to slow 
diffusion, but do implement monitoring and reporting requirements 
(Bipartisan Policy Center) or informed consent requirements 
(REGROW Act). As I will address in the following subsection, 
weaknesses in each of these proposals renders them impracticable 
and unwise. 
2.   Caplan and West 
In a 2014 article in a scientific journal, Caplan and West proposed 
an alternate regulatory pathway that would allow the marketing of 
regenerative medicine therapies without any evidence of efficacy.183 
Under their proposal, a therapy would be subject to two regulatory 
                                                                                                                 
 181. Eichler, supra note 77, at 428. 
 182. See id. at 427. 
 183. Caplan & West, supra note 177, at 561. 
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steps. The first step would establish product safety through 
preclinical assessments of the therapy’s proposed mechanism of 
action and Phase 1 clinical trials.184 Based on this preliminary 
evidence, the therapy would be approved for marketing.185 In the 
second step, postmarketing studies would rely on inputs from 
physicians and patients to “capture, in real time, the full experience 
of a large population.”186 Effectiveness would be established through 
this postmarket evidence-gathering.187 The sponsor would also be 
required to conduct a five-to-ten year follow up to establish the long-
term safety of the procedures.188 Only those therapies intended to 
provide a meaningful advancement in the treatment of a serious or 
life-threatening disease would be eligible.189 The product’s diffusion 
through the marketplace would be controlled through distribution 
restrictions, physician training, and credentialing.190 Under Caplan 
and West’s proposal, the therapies on the market would not be 
considered “investigational,” so they would be subject to the same 
coverage and reimbursement policies as therapies that are approved 
after demonstrating efficacy.191 
3.   The Bipartisan Policy Center Report 
The Bipartisan Policy Center issued a report in December 2015 
entitled, “Advancing Regenerative Cellular Therapies.”192 The report 
called for the creation of a new regulatory pathway for regenerative 
medicine therapies regulated as biologics.193 To qualify, a product 
would have to meet a set of criteria designed to exclude the highest 
risk therapies.194 Therapies that fall under this new pathway would be 
                                                                                                                 
 184. Id. 
 185. Id. 
 186. Id. 
 187. Id. 
 188. Id. 
 189. Caplan & West, supra note 177, at 561. 
 190. Id. at 562. 
 191. Id. at 562. 
 192. BIPARTISAN POLICY CTR., ADVANCING REGENERATIVE MEDICINE: MEDICAL INNOVATION FOR 
HEALTHIER AMERICANS 1 (2015). 
 193. Id. at 12. 
 194. Id. at 13–15. The qualifying products either would be (1) (A) intended for homologous use and 
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conditionally approved based on Phase 1 and Phase 2 trials 
demonstrating safety and efficacy.195 Patients would have access to 
these conditionally-approved therapies subject to monitoring and 
reporting requirements to the FDA.196 Within three years of receiving 
conditional approval, the sponsor would be required to submit a 
biologics license application based on the accrued data of actual 
use.197 
4.   The REGROW Act 
In March 2016, Mark Kirk, a Republican senator from Illinois, 
introduced a bill entitled, “Reliable and Effective Growth for 
Regenerative Health Options that Improve Wellness” or the 
“REGROW” Act.198 In his press release announcing the REGROW 
Act, Senator Kirk stated that the bill “builds on [the December 2015 
Bipartisan Policy Center report].”199 The bill ultimately died,200 but 
offers another example of a reform proposal. 
Under the REGROW Act, the FDA would have been required to 
establish a program to “conditionally approve” certain regenerative 
medicine therapies that demonstrated safety and a “reasonable 
expectation of effectiveness.”201 Importantly, Phase 3 clinical trials 
would not be required for those therapies before they became 
                                                                                                                 
(B) more-than-minimally manipulated but where processing does not alter the cells’ or tissues’ relevant 
biological characteristics or function; or (2) (A) intended for non-homologous use that helps perform or 
restore function in the recipient (“to reflect attributes of stem cells to differentiate and co-opt biological 
processes to restore the cells/tissue into which they are placed”) and (B) either minimally-manipulated 
or more-than-minimally manipulated but where processing does not alter the cells’ or tissues’ relevant 
biological characteristics or function. Id. Therapies that fall into this category include autologous 
culture-expanded adipose mesenchymal stem cells for subcutaneous injection, autologous adipose 
stromal vascular fraction to reduce arthritic inflammation in joints, and allogeneic or autologous bone 
marrow or cord tissue-derived mesenchymal stem cells for treatment of acute ischemic heart attack. Id. 
 195. Id. at 13. 
 196. Id. 
 197. Id. 
 198. S. 2689, 114th Cong. (2016). An identical bill, H.R. 4762, was introduced in the House by 
Representative Mike Coffman, R-CO. H.R. 4762, 114th Cong. (2016). 
 199. Press Release, supra note 172; see also Cade Hildreth, Kirk, Manchin, Collins Introduce Bill to 
Speed Development of Regenerative Medicine, BIOINFORMANT (Mar. 16, 2016), 
https://www.bioinformant.com/kirk-manchin-collins-introduce-bill-to-speed-development-of-
regenerative-medicine/#more-5609 [http://perma.cc/GVY5-4JRZ]. 
 200. See S. 2689 – REGROW Act, supra note 169. 
 201. S. 2689, 114th Cong. § (2)(b) (2016). 
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available to patients.202 To be eligible, products would also have to: 
(1) not provoke an unintended immune response; (2) not be 
genetically modified; and (3) be exclusively for a use that performs, 
or helps achieve or restore, the same or similar function in the 
recipient as in the donor.203 Within five years after conditional 
approval, the therapy’s sponsor would be required to apply for the 
therapy’s approval as a biologic.204 The only proposed limitation on 
patient access would require informing patients receiving the 
conditionally approved therapy of the therapy’s conditional status.205 
None of these proposals strikes an appropriate balance between 
access and risk because none require two necessary elements: (1) 
significant evidence of safety and effectiveness, and (2) meaningful 
measures to control the product’s diffusion. 
B.   Theorizing Adaptive Licensing 
Adaptive licensing is an example of adaptive management, a 
regulatory reform model that envisions administrative agencies 
making iterative decisions instead of a single “grand decision.”206 
Adaptive management responds to criticism that agency decision-
making is overly focused on front-end analysis that must be 
conducted and concluded prior to finalizing a regulatory decision.207 
Such focus, critics charge, requires agency decision-makers to falsely 
assume that they can predict the market and nonmarket effects of 
their decisions, and leads to regulatory ossification and 
inflexibility.208 Adaptive management responds by proposing an 
                                                                                                                 
 202. Id. 
 203. Id. § (2)(b)(2)–(5). 
 204. Id. § (2)(b). 
 205. Id. § (2)(c). 
 206. Robin Kundis Craig & J.B. Ruhl, Designing Administrative Law for Adaptive Management, 67 
VAND. L. REV. 1, 7 (2014). 
 207. Id. 
 208. See, e.g., Thomas O. McGarity, Some Thoughts on “Deossifying” the Rulemaking Process, 41 
DUKE L.J. 1385, 1392 (1992); J.B. Ruhl & James Salzman, Mozart and the Red Queen: The Problem of 
Regulatory Accretion in the Administrative State, 91 GEO. L.J. 757, 841 (2003) (addressing the problem 
of regulatory accretion); Mark Seidenfeld, Bending the Rules: Flexible Regulation and Constraints on 
Agency Discretion, 51 ADMIN. L. REV. 429, 457 (evaluating impact of ex ante restraints on agency 
decision-making on predictability, accountability, and flexibility); Richard B. Steward, Administrative 
Law in the Twenty-First Century, 78 N.Y.U. L. REV. 437, 447 (2003) (identifying inflexibility and rapid 
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iterative process by which an administrative agency decides a 
regulatory outcome through a multistep process that includes 
defining the problem, identifying goals and options, implementing 
action, and monitoring and evaluating outcomes.209 
Adaptive management was born from a concern that conventional 
methods for natural resource management were at odds with the 
dynamic nature of ecosystems.210 But the same principles can apply 
in a variety of other regulatory situations. Professor Robin Kundis 
Craig delineates three factors that suggest when adaptive 
management is appropriate: high uncertainty, high controllability, 
and low risk.211 High uncertainty describes a decision-maker’s level 
of understanding about how the regulatory context responds to 
interventions.212 As uncertainty rises, confidence in a front-end 
model of decision-making erodes, and adaptive management 
becomes more appropriate.213 High controllability is the degree to 
which a decision-maker can manipulate the regulatory 
environment.214 Higher controllability means that the decision-maker 
has a greater capacity to intervene in the problem and can engage in 
more experimentation and option testing.215 Low risk describes the 
chance that experimentation or interventions can lead to irreversible 
adverse consequences. High risk makes adaptive management less 
appropriate.216 
Under this rubric, adaptive licensing is appropriate for regenerative 
medicine therapies under the first principle of high uncertainty. But 
the second and third principles of high controllability and low risk 
highlight the flaws with applying adaptive licensing to regenerative 
medicine therapies. Limits to the FDA’s authority, challenges with 
implementation, and concerns with shortcutting premarket evidence 
                                                                                                                 
obsolescence as problems of command-and-control regulation). 
 209. Kundis Craig & Ruhl, supra note 206, at 7. 
 210. Id. at 17. 
 211. Id. at 19. An optional fourth factor, “dynamic system,” is not applicable to the drug approval 
regime, so I have omitted it from my discussion. 
 212. Id. 
 213. Id. 
 214. Id. 
 215. Kundis Craig & Ruhl, supra note 206, at 19. 
 216. Id. 
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generation are sufficiently serious to limit the appeal of such an 
approach. 
1.   High Uncertainty 
The first principle for adaptive management is that the regulatory 
situation involves uncertainty.217 An approval decision for 
regenerative medicine therapies will often involve uncertainty, 
particularly if a therapy is biologically complex, is difficult to define 
or characterize, or requires long-term evaluation of risk or efficacy. 
First, regenerative medicine therapies present approval challenges 
due to the presence of living cells.218 Biologics contain thousands to 
millions of atoms formed into intricate designs.219 Because the 
behavior of a cell depends on its microenvironment, changing the 
cell’s micro-environment from a laboratory setting to an animal 
model to a human means that the cells are exposed to different 
factors in each setting.220 This complicates safety and efficacy studies 
because the conditions in the laboratory may not accurately mimic 
the cell’s environment in a human.221 Furthermore, once transplanted 
into a human, the cells may change over time.222 Cells may 
differentiate into unwanted cell types.223 They might also develop 
unwanted functions; for example, cardiomyocyte-like cells could 
generate electrical activity that is not coordinated with the rest of the 
                                                                                                                 
 217. Id. at 19. 
 218. Although most do, not all regenerative medicine therapies use living cells. For example, the 
bioengineered blood vessel marketed by Humacyte does not contain living cells. See, e.g., Abigail Xie, 
Bioengineered Blood Vessels Shown to be Effective in Patients with Kidney Failure, CHRONICLE (May 
26, 2016), http://www.dukechronicle.com/article/2016/05/bioengineered-blood-vessels-shown-to-be-
effective-in-patients-with-kidney-failure [http://perma.cc/RQ4S-34XE]. 
 219. Robin Feldman, Regulatory Property: The New IP, 40 COLUM. J. L. & ARTS 53, 82 (2016) 
(citing Bryan Liang, Regulating Follow-On Biologics, 44 HARV. J. ON LEGIS. 363, 369 (2007)); Robert 
N. Sahr, The Biologics Price Competition and Innovation Act: Innovation Must Come Before Price 
Competition, B.C. INTELL. PROP. & TECH. F., July 19, 2009, at 2. 
 220. The Committee for Advanced Therapies (CAT) & the CAT Scientific Secretariat, supra note 36, 
at 196–97. 
 221. Id.; Melissa K. Carpenter et al., Developing Safe Therapies from Human Pluripotent Stem Cells, 
27 NATURE BIOTECHNOLOGY 606, 609 (2009). 
 222. U.S. FOOD & DRUG ADMIN., CONSIDERATIONS FOR THE DESIGN ON EARLY-PHASE CLINICAL 
TRIALS OF CELLULAR AND GENE THERAPY PRODUCTS: GUIDANCE FOR INDUSTRY 4 (2015) [hereinafter 
EARLY-PHASE: GUIDANCE]. 
 223. Id. 
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heart.224 Similarly, cells may migrate to an unintended location 
within the recipient’s body.225 
A second related problem is the heterogeneous nature of many 
regenerative medicine products; they contain a variety of cell types, 
with one or more being the “active agent.”226 Because defining and 
controlling a product is essential for assessing a product’s safety and 
efficacy, products with multiple living cell types that respond to their 
environment—and are therefore in flux—challenge researchers’ 
abilities to properly characterize and control a product.227 Autologous 
products that are uniquely sourced for each patient compound this 
issue because of challenges in controlling lot-to-lot variability.228 
Third, living cells’ unique characteristics may require regenerative 
medicine therapies to undergo prohibitively long clinical trials to 
demonstrate efficacy or to uncover risks.229 To be effective, a 
regenerative therapy must repair the damaged tissue as intended.230 
But the mechanism of action for tissue repair and regeneration is 
often unknown and may be a result of cell secretions by the 
transplanted cells rather than donor cell repopulation of the targeted 
tissues.231 Given these unknowns, testing the therapy’s long-term 
clinical outcome to determine whether the cells differentiated as 
intended and then functionally repaired the damaged tissue can take a 
long time—even several years.232 This length of time may make 
clinical trials expensive and difficult because participants may be 
                                                                                                                 
 224. Id. 
 225. Id. 
 226. Jeffrey L. Fox, FDA Scrutinizes Human Stem Cell Therapies, 26 NATURE BIOTECHNOLOGY 598, 
599 (2008); Robert A. Preti, Bringing Safe and Effective Cell Therapies to the Bedside, 23 NATURE 
BIOTECHNOLOGY 801, 801–02 (2005). 
 227. Fox, supra note 226, at 598. 
 228. EARLY-PHASE: GUIDANCE, supra note 222, at 5. 
 229. The Committee for Advanced Therapies (CAT) & the CAT Scientific Secretariat, supra note 36, 
at 197. 
 230. Id. 
 231. Stefanie Dimmeler et al., Translational Strategies and Challenges in Regenerative Medicine, 20 
NATURE MED. 814, 819 (2014). 
 232. The Committee for Advanced Therapies (CAT) & the CAT Scientific Secretariat, supra note 36, 
at 197. 
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unable to attend follow-up appointments or may die from their 
underlying conditions or other causes.233 
Uncovering risks may also be a long-term project. Stem cells that 
are undifferentiated, or not completely differentiated, risk turning 
into tumor cells.234 Pluripotent stem cells can produce teratomas, 
which are an accumulation of many different cell types into a benign 
tumor.235 These teratomas can fill anatomical space with potentially 
disastrous consequences.236 They can also dedifferentiate and 
develop into a malignant form.237 Although determining the 
tumorigenicity of stem cells will be a main focus of preclinical 
studies, clinical factors—such as the site of implantation and the 
number of cells implanted—will impact a therapy’s tumorigenicity238 
and will be a continued focus of long-term clinical trials.239 
Adaptive licensing can address uncertainty by enabling regulators 
and sponsors to design an approval pathway for a regenerative 
medicine therapy that addresses its particular challenges. For 
therapies that would take an inordinate amount of time to test in a 
clinical trial, perhaps because the targeted condition is rare or 
because the mechanism of action is slow-moving, an initial license 
based on an unvalidated surrogate endpoint would allow limited early 
patient access, followed by a subsequent lifting of restrictions based 
on demonstrated success in meeting defined clinical endpoints.240 If 
the concern is ensuring effectiveness in a real-world population, an 
initial license might be based on an explanatory trial with closely-
monitored inclusion criteria, and the postmarketing study would be a 
pragmatic, randomly-controlled trial that evaluates effectiveness in a 
real-world, clinical setting.241 If the concern is uncovering rare 
                                                                                                                 
 233. Id. 
 234. Carpenter, supra note 221, at 610. 
 235. Fox, supra note 226, at 599. 
 236. Id. 
 237. Id. 
 238. Carpenter, supra note 221, at 610. 
 239. See Evgenios Neofytou et al., Hurdles to Clinical Translation of Human Induced Pluripotent 
Stem Cells, 125 J. CLINICAL INVESTIGATION 2551, 2553 (2015); see also Amariglio, supra note 134, at 
226 (describing diagnosis of brain tumor in boy four years after treatment with human fetal neural cells). 
 240. Eichler, supra note 77, at 431–32. 
 241. Id. at 430. 
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adverse events, an initial license could be based on a randomly-
controlled trial, and the postmarket study could be a long-term 
evaluation through observational studies or patient registries.242 
2.   High Controllability 
The second principle for adaptive management advises high 
controllability.243 Unlike the first principle of high uncertainty, which 
is met in the regenerative medicine context, evidence of 
controllability is less robust. Controllability in a regenerative 
medicine scenario implicates four components: (1) the FDA’s 
authority to approve biologics on the basis of less-robust evidence of 
safety, purity, and potency; (2) the FDA’s authority to require 
postmarketing studies from sponsors; (3) the FDA’s authority to 
control the diffusion of the therapies; and (4) the FDA’s ability to 
appropriately respond to new evidence.244 Regarding the first 
component, the FDA does not have the authority to approve biologics 
unless they are shown to be safe, pure, and potent.245 This limits, but 
does not eliminate, the FDA’s current ability to approve biologics 
that have not undertaken Phase 3 trials. Second, the FDA’s authority 
to require postmarketing studies is limited to specific 
circumstances.246 A broader grant of power is required if adaptive 
licensing is pursued. Regarding the third component, the FDA has the 
authority to control the diffusion of the product through its use of 
                                                                                                                 
 242. See id. at 431–32; Gibson & Lemmens, supra note 168, at 207–08. 
 243. Craig & Rhule, supra note 206, at 19. 
 244. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY EXPEDITED PROGRAMS FOR SERIOUS 
CONDITIONS–DRUGS AND BIOLOGICS 20 (2014) [hereinafter GUIDANCE FOR INDUSTRY EXPEDITED 
PROGRAMS]; John D. Balian et al., Roadmap to Risk Evaluation and Mitigation Strategies (REMS) 
Success, 1 THERAPEUTIC ADVANCES IN DRUG SAFETY 21, 21 (2010); Frequently Asked Questions About 
Therapeutic Biological Products, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvala
pplications/therapeuticbiologicapplications/ucm113522.htm [https://perma.cc/CHV5 BD85] (last 
updated July 7, 2015); Notice to Industry: Postmarketing Requirements–Postmarket Studies and 
Clinical Trials, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ucm292758.htm 
[https://perma.cc/TYV2-CTS8] (last updated Feb. 12, 2016) [hereinafter Notice to Industry: 
Postmarketing Requirements]. 
 245. Frequently Asked Questions About Therapeutic Biological Products, supra note 244. 
 246. Notice to Industry: Postmarketing Requirements, supra note 244. 
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Risk Mitigation and Enforcement Measures (REMS).247 But the 
fourth component, the ability to respond appropriately to new 
evidence, will challenge the FDA for two distinct reasons: (1) 
withdrawing a product from the marketplace—even if legally 
possible—will be politically difficult, and (2) structuring an 
agreement with a sponsor that is both flexible enough to respond to 
new evidence yet certain enough to be attractive to sponsors may not 
be feasible. 
a.   Approval Authority 
As an initial matter, it is necessary to determine whether the FDA 
has the authority to approve biologics on less robust evidence than is 
traditional.248 Fundamentally, biologics may only be approved based 
on evidence that demonstrates continued safety, purity, and 
potency.249 Potency is interpreted to require effectiveness.250 Proof of 
effectiveness generally requires adequate and well-controlled clinical 
trials, unless either the FDA waives them as inapplicable or an 
alternate method is adequate to substantiate effectiveness.251 One 
such alternate method to substantiate effectiveness is the use of 
validated surrogate endpoints. The existing RMAT and Accelerated 
Approval pathways codify this understanding.252 But the FDA cannot 
approve a therapy based on a body of evidence that fails to show that 
the product is safe, pure, and potent.253 Such a move would simply 
violate the FDA’s legal mandate to only approve a product where 
existing evidence supports a conclusion of continued safety, purity, 
and potency. 
                                                                                                                 
 247. Balian et al., supra note 244, at 21. 
 248. GUIDANCE FOR INDUSTRY EXPEDITED PROGRAMS, supra note 244, at 10. 
 249. 42 U.S.C. § 262 (a)(2)(C)(i)(I) (Supp. 2017). 
 250. 21 C.F.R. § 600.3(5) (2012); U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY PROVIDING 
CLINICAL EVIDENCE OF EFFECTIVENESS FOR HUMAN DRUGS AND BIOLOGICAL PRODUCTS 4 (1988). 
 251. 21 C.F.R. § 314.126 (a), (c), (e) (2002). 
 252. Peter Marks, This Is Not a Test: RMAT Designation Goes Live, U.S. FOOD & DRUG ADMIN. 
(Mar. 21, 2017), https://blogs.fda.gov/fdavoice/index.php/2017/03/this-is-not-a-test-rmat-designation-
goes-live/ [https://perma.cc/V84Y-9Z8B]. 
 253. 42 U.S.C. § 262 (a)(2)(C). 
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b.   Postmarketing Authority 
An adaptive licensing scheme also requires that sponsors agree to 
postmarketing studies as a condition of earlier approval.254 This 
second component raises an additional concern of insufficient 
authority on the part of the FDA. The FDA only has clear statutory 
authority to mandate postmarketing studies or trials based on safety 
risks or accelerated approval. The Food and Drug Administration 
Amendments Act of 2007 authorized the FDA to require the sponsor 
of an approved biologic to conduct postmarketing studies or clinical 
trials if the FDA became aware of new information about a serious 
risk associated with the biologic since its approval.255 This authority 
limits the FDA to requiring additional studies based only on safety 
concerns, not on effectiveness concerns.256 The FDA also may 
require sponsors to agree to conduct postmarketing studies as a 
condition of receiving approval based on a surrogate or intermediate 
endpoint.257 The pathways that enable the use of surrogate or 
intermediate endpoints, Accelerated Approval and the RMAT 
designation, are limited to therapies that are “intended to treat, 
modify, reverse or cure a serious or life-threatening disease or 
condition; and . . . have the potential to address unmet medical needs 
for such a disease or condition.”258 
But an adaptive licensing framework envisions accelerated 
approval conditioned on postmarketing studies for a greater scope of 
products than those covered by the FDA’s current statutory 
                                                                                                                 
 254. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY POSTMARKETING STUDIES AND 
CLINICAL TRIALS—IMPLEMENTATION OF SECTION 505(O)(3) OF THE FEDERAL FOOD, DRUG, AND 
COSMETIC ACT 2–3 (2011) [hereinafter GUIDANCE FOR INDUSTRY POSTMARKETING STUDIES AND 
CLINICAL TRIALS]. 
 255. Food and Drug Administration Amendments of 2007, Public L. No. 110-85, § 901, 121 Stat. 823 
(codified as 21 U.S.C. § 355(o)(3)(C)); 42 U.S.C. § 262(a)(2)(D) (Supp. 2016) (cross-referencing the 
PHSA with the FDCA); GUIDANCE FOR INDUSTRY POSTMARKETING STUDIES AND CLINICAL TRIALS, 
supra note 254, at 4, 16; see, e.g., Rebecca S. Eisenberg & W. Nicholson Price II, Promoting 
Healthcare Innovation on the Demand Side, 10 J. L. AND BIOSCIENCES 3, 10–13 (2017); Riley, supra 
note 17, at 458–60, (discussing postmarketing provisions of FDAAA). 
 256. Riley, supra note 17, at 465–66. 
 257. 21 U.S.C. § 356(g)(5) (Supp. 2016); Kenneth A. Oye et al., Legal Foundations of Adaptive 
Licensing, 94 CLINICAL PHARMACOLOGY & THERAPEUTICS 309, 310 (2013). 
 258. 21 U.S.C. § 356(g)(2)(B–C). The limitations for accelerated approval of drugs or biologics are 
substantively the same. See id. § 356(c)(2)–(3). 
42
Georgia State University Law Review, Vol. 34, Iss. 3 [2018], Art. 3
https://readingroom.law.gsu.edu/gsulr/vol34/iss3/3
2018] REFORMING REGENERATIVE MEDICINE REGULATION 673 
authority.259 In such a situation, where the FDA seeks to impose 
postmarketing requirements outside of its statutory permissions for 
safety issues and accelerated pathways, the FDA’s authority is 
murky. The FDA regularly requests that sponsors conduct 
postmarketing studies, and sponsors commit in writing to the FDA to 
conduct such postmarketing commitments.260 But the FDA does not 
have clear authority to condition approval on “voluntary” 
postmarketing studies.261 
The biologics context can be analogized to Charles Steenburg’s 
analysis of the new drug context.262 Significantly, the statute 
governing the licensing of biologics is nondiscretionary: “a biologics 
license shall be issued upon a determination . . . that the 
establishment(s) and the product meet the applicable requirements 
established in this chapter.”263 And such approval “shall constitute a 
determination that the establishment(s) and the product meet 
applicable requirements to ensure the continued safety, purity, and 
potency of such products.”264 Thus, any requirement on the part of 
the FDA to require postmarketing studies as a condition of approval 
would lead to an incongruous result. Namely, the FDA would either 
(1) implicitly admit that its approval did not constitute a 
determination that the product meets the requirements to ensure 
continued safety, purity, and potency of such product, or (2) deny the 
sponsor its statutory right to receive premarketing approval for a 
biologic which has met the applicable statutory requirements.265 
In summary, combining the sources of FDA authority for approval 
and postmarketing studies reveals a gap where the FDA does not 
currently have the ability to approve products that have not been 
shown to be safe, pure, and potent, or to require postmarketing 
                                                                                                                 
 259. See Steenburg, supra note 81, at 361. 
 260. U.S. FOOD & DRUG ADMIN., REPORT TO CONGRESS, REPORTS ON POSTMARKETING STUDIES, 
FDAMA 130, at 1 (2001); Steenburg, supra note 81, at 335–36. 
 261. See Steenburg, supra note 81, at 357. 
 262. Id. at 349 (arguing that the FDA’s authority to condition approval of new drugs on “voluntary” 
commitments to conduct postmarketing studies conflicts with the FDA’s nondiscretionary mandate to 
approve new drugs that meet the requirements of section 505(e)). 
 263. 21 C.F.R § 601.4 (2016) (emphasis added). 
 264. 21 C.F.R § 601.2(d). 
 265. See Steenburg, supra note 81, at 358. 
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studies for regenerative medicine products that neither are subject to 
approval under a fast-track pathway nor raise new safety concerns. 
To implement a cohesive adaptive licensing scheme, it would 
therefore be necessary for Congress to grant the FDA authority to 
require postmarketing studies as a condition of earlier approval for 
those products neither designated as RMATs (or otherwise reviewed 
under a fast-track procedure) nor for which safety evidence supports 
requiring postmarketing obligations. 
c.   Controlling Diffusion 
The third component of controlling the regulatory environment 
involves the FDA’s ability to control the diffusion of a regenerative 
medicine therapy in the marketplace.266 This would allow regulators 
to limit initial access to patients with the most appropriate 
risk/benefit characteristics.267 Particularly for regenerative therapies 
that have not been previously approved for use in humans, controls 
would be needed to limit access until significant uncertainties are 
resolved.268 Numerous methods exist to control diffusion, including 
limiting use of the therapy to certain patient populations, restricting 
off-label prescribing, and ensuring that prescribers and pharmacists 
have received advanced certification. The FDA has the authority to 
require such controls under its power to require sponsors to develop 
and implement REMS, including Elements to Assure Safe Use 
(ETASU). 269 These include requiring that: 
 
 health care providers have particular training 
or experience, or are specially certified; 
                                                                                                                 
 266. Turner & Knoepfler, supra note 23, at 156. 
 267. Eichler, supra note 77, at 429; Caplan & West, supra note 177, at 562. 
 268. R. Alta Charo, Speed Versus Safety in Drug Development, in FDA IN THE 21ST CENTURY: THE 
CHALLENGES OF REGULATING DRUGS AND NEW TECHNOLOGIES 251, 263 (I. Glenn Cohen & Holly F. 
Lynch, eds., 2015); Efthimios Parasidis, FDA’s Public Health Imperative: An Increased Role for 
Postmarket Analysis, in FDA IN THE 21ST CENTURY: THE CHALLENGES OF REGULATING DRUGS AND 
NEW TECHNOLOGIES 286, 293 (I. Glenn Cohen & Holly F. Lynch, eds., 2015). 
 269. The Public Health Service Act provides that license applications for biological products are 
subject to the REMS provisions of the FDCA. 42 U.S.C. § 262(a)(2)(D) (Supp. 2017). 
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 pharmacies, practitioners, or health care 
settings that dispense the therapy are specially 
certified; 
 the therapy be dispensed to patients only in 
certain health care settings; 
 the therapy be dispensed to patients with 
evidence or other documentation of safe-use 
conditions, such as laboratory results; 
 patients be subject to certain monitoring; or 
 patients be enrolled in a registry.270 
 
Use of these elements would enable the FDA and sponsors to 
control the diffusion of a regenerative medicine therapy while 
continuing postmarket studies to further evaluate safety and 
effectiveness. 
d.   Responding to Evidence 
The fourth component of controlling the regulatory environment is 
the FDA’s ability to react and respond to new evidence generated in 
postmarketing trials and studies.271 Adaptive licensing frameworks 
envision that postmarketing studies will generate evidence to support 
either eliminating the risk mitigation measures or removing the 
therapy from the market in the event that safety or efficacy issues 
arise.272 Just like the many drugs that look promising in Phase 2 trials 
but fail Phase 3 trials due to safety or efficacy problems,273 it is likely 
                                                                                                                 
 270. Id. § (f)(3). Although the statute limits the FDA requiring ETASU for drugs “shown to meet the 
standard” of safety and efficacy, the application of ETASU on drugs approved under the accelerated 
approval pathway based on surrogate endpoints suggest that “effective” is liberally interpreted to apply 
to all drugs approved by the FDA (which are, tautologically, safe and effective). Id. 
 271. Steenburg, supra note 81, at 320. 
 272. See Gibson & Lemmens, supra note 168, at 214–15. 
 273. A recent study published in Nature Biotechnology surveyed the drug development success rates 
for over 7,000 drugs from 2003 to 2011. The authors demonstrated that only half of drug indications in 
Phase 3 trials ultimately received approval from the FDA. Michael Hay et al., Clinical Development 
Success Rates for Investigational Drugs, 32 NATURE BIOTECHNOLOGY 40, 44 (2014); U.S. FOOD & 
DRUG ADMIN., 22 CASE STUDIES WHERE PHASE 2 AND PHASE 3 TRIALS HAD DIVERGENT RESULTS 
(2017); see also ISSCR Opposes the REGROW Act, INT’L SOC’Y FOR STEM CELL RES. (Sept. 15, 2016), 
http://www.isscr.org/professional-resources/news-publicationsss/isscr-news-articles/article-
listing/2016/09/15/isscr-opposes-the-regrow-act [https://perma.cc/H4RQ-NUJ9] (stating that as many as 
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that if the FDA approved therapies under an adaptive licensing 
scheme based on less rigorous evidence, those therapies would 
similarly demonstrate a lack of safety or efficacy in postmarketing 
studies. This suggests that an adaptive licensing framework would 
require the FDA to have a robust ability to respond to safety or 
effectiveness concerns. Current, its ability is mixed. 
The FDA has authority to respond to sponsor failures to complete 
REMS or mandatory postmarketing commitments. Under the relevant 
statutes, a sponsor that fails to abide by a REMS or fails to conduct a 
postmarketing study may not introduce the drug into interstate 
commerce.274 Doing so would constitute a misbranding violation, 
which could result in product seizures.275 The FDA also has the 
authority to react to evidence that a product is not safe or effective.276 
The biologics regulations also provide that the FDA can withdraw a 
license in the event the product is not safe and effective for its 
intended uses, or is misbranded with respect to any such use.277 
But the FDA is subject to political pressures as well. Once a new 
therapy is on the market, it likely will be politically difficult to 
withdraw it, even if safety and efficacy concerns arise.278 Sponsors of 
drug trials have been very successful in motivating grassroots support 
for potential therapies, and the lobbying power of the biologics and 
pharmaceutical industry raises concerns that regulators will be unable 
to avoid industry capture.279 
Finally, creating an agreement that both allows for the FDA to 
react to new evidence and is sufficiently attractive to a product 
sponsor will likely prove difficult. From the perspective of a drug 
sponsor, participating in adaptive licensing involves a trade-off 
                                                                                                                 
40% of drug and biotechnology products that enter Phase 3 fail). 
 274. 21 U.S.C. § 355(p)(1)-(2) (Supp. 2016). 
 275. 21 U.S.C. § 355(d); 21 U.S.C. § 334 (2011). Compare United States v. Sandoz Pharm. Corp., 
894 F.2d 825, 826 (6th Cir. 1990) (upholding seizure where the defendant failed to file a new drug 
application before introducing product into interstate commerce), with United States v. 225 Cartons, 687 
F. Supp. 946, 962 (D. N.J. 1988) (upholding seizure of drugs where new drug application had not been 
filed with FDA pursuant to 21 U.S.C. § 355), aff'd, 871 F.2d 409 (3d Cir. 1989). 
 276. 21 U.S.C. § 355(d). 
 277. 21 C.F.R. § 601.5(b)(vi) (2017). 
 278. Gibson & Lemmens, supra note 168, at 216–17. 
 279. See Overcoming Premarket Syndrome, supra note 81, at 275. 
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between rules that are certain—even if not ideal—and rules that are 
flexible but uncertain.280 For sponsors, the benefit of adaptive 
licensing is earlier access to the market.281 But market forces could 
dampen this benefit. If payors refuse to cover a therapy, the sponsor 
would lose this prospective benefit.282 Similarly, even if payors agree 
to cover the therapy, an overly-restricted pool of patients would 
lessen the financial benefits to sponsors, a problem that could be 
compounded by FDA-enforced market exclusivities. Because the 
FDA grants a new biologic twelve years of marketing exclusivity, a 
limit on the sponsor’s ability to receive payment for a product during 
this period would act as a significant disincentive to participate in 
adaptive licensing.283 Furthermore, if there is significant uncertainty 
about how the FDA will respond to newly created evidence, such as 
what type and length of studies will be needed to lift restrictions, 
sponsors may decline to participate.284 
The analysis of controllability reveals flaws in the application of 
adaptive licensing to regenerative medicine therapies under the 
FDA’s current authority. But even assuming that Congress granted 
additional authority for proper implementation of an adaptive 
licensing framework, a robust agreement between the therapy’s 
sponsor, the FDA—and potentially payors—would be required to 
properly incentivize sponsor participation. The fatal flaw with all 
regenerative medicine adaptive licensing proposals, however, is the 
absence of low risk. 
3.   Low Risk 
The third principle for adaptive management, low risk, is not met 
by adaptive licensing of regenerative medicine therapies. Given the 
diversity of regenerative medicine therapies, they array widely across 
a measure of risk. But for many therapies, early approval increases 
                                                                                                                 
 280. Price & Rai, supra note 173, at 1060. 
 281. Charo, supra note 268, at 258. 
 282. Id. at 262. 
 283. Id. at 257. 
 284. Id. at 254. 
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the risk that patients will either incur opportunity costs if the therapy 
does not work or suffer physical harms previously undiscovered.285 
Most biologics that are investigated in clinical trials do not work. 
A 2016 study of clinical development success rates over ten years, 
from 2006 through 2015, involved almost 10,000 phase transitions 
and found that only 11.5% of biologics that entered Phase 1 trials 
ultimately received FDA approval.286 Of those biologics in Phase 3 
trials, only half of them received FDA approval.287 Another study of 
drug development success rates for over 7,000 drugs from 2003 to 
2011 tells a similar story: only slightly more than half of biologics in 
Phase 3 trials ultimately received FDA approval.288 This data is 
important because it means that if regenerative medicine therapies 
are provided to patients before Phase 3 trials are complete, we should 
expect around half to fail to provide a benefit that outweighs the risk. 
Such a system would make the initial patient population akin to a 
class of clinical trial participants, but without the protections 
provided by clinical trials. 
Physical harm represents another risk. Although a product’s 
REMS strategy could include measures to mitigate the likelihood of 
harm—including communication tools such as distribution of a 
medication guide,289 or communication by the sponsor to health care 
providers of risks and mitigating measures—concerns remain.290 
Current evidence about drugs and biologics approved under an 
accelerated pathway suggest caution. Existing accelerated pathways 
are similar to those suggested by adaptive licensing, and many 
therapies that are approved under accelerated pathways based on 
                                                                                                                 
 285. See Gibson & Lemmens, supra note 168, at 207. 
 286. DAVID W. THOMAS ET AL., CLINICAL DEVELOPMENT SUCCESS RATES 2006–2015, at 19–20 
(2016). 
 287. Id. 
 288. Michael Hay et al., supra note 273, at 44; U.S. FOOD & DRUG ADMIN., supra note 273; see also 
ISSCR Opposes the REGROW Act, supra note 273 (stating that as many as 40% of drug and 
biotechnology products that enter Phase 3 fail). 
 289. 21 U.S.C. § 355-1(e)(2) (Supp. 2017). A medication guide highlights a safety concern and can 
recommend mitigating measures such as weighing risks versus benefits, observing certain symptoms 
that could prevent or mitigate a serious side effect, highlighting patient populations that are 
contraindicated for the therapy, and stressing the importance of following the dosing regimen. 21 C.F.R. 
§ 208.20 (2008). 
 290. 21 U.S.C. § 355-1(e)(2)-(3); Eichler, supra note 77, at 429. 
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surrogate or intermediate endpoints fail to demonstrate the desired 
ultimate clinical benefit.291 
Two studies published in 2017 demonstrate the extent of the 
problem. Dr. Aaron Kesselheim and his colleagues published a study 
that showed that the medicines approved under expedited regulatory 
pathways had a 38% higher rate of safety changes to product labels 
than those approved under a traditional pathway.292 The expedited 
drugs also had a 48% higher rate of changes to black box warnings, 
which are warnings designed to disclose serious or life-threatening 
risks, or contraindications.293 Another study found that nearly one in 
three drugs approved by the FDA have safety issues after approval, 
and the percentage is even higher for biologics and medicines 
approved under an accelerated pathway.294 
The use of surrogate endpoints is partly to blame. Although 
surrogate endpoints allow sponsors to reduce the size, time, and cost 
of clinical trials,295 they also pose challenges. A baseline challenge is 
identifying those surrogate endpoints that ultimately demonstrate the 
desired clinical benefit. Correlation does not equal causation, and 
there is a risk that a beneficial change in a surrogate endpoint will not 
necessarily cause a benefit in a clinical endpoint.296 For example, a 
                                                                                                                 
 291. An intermediate clinical endpoint is a “clinical endpoint that can be measured earlier than 
irreversible morbidity or mortality.” 21 U.S.C. § 356(c)(1)(A). A “surrogate endpoint” is a biomarker 
that is intended to substitute for a clinical endpoint. INST. OF MED., EVALUATION OF BIOMARKERS AND 
SURROGATE ENDPOINTS IN CHRONIC DISEASE 3 (Christine M. Michael & John R. Ball, eds., 2010), 
https://www.nap.edu/read/12869/chapter/2#3 [https://perma.cc/ZNG9-YXEN] [hereinafter IOM, 
BIOMARKERS]. Intermediate or surrogate endpoints include measures such as imaging data or markers in 
the blood that predict, but do not prove, ultimate endpoints. Kelly Servick, Under 21st Century Cures 
Legislation, Stem Cell Advocates Expect Regulatory Shortcuts, SCIENCE MAG., AAAS (Dec. 12, 2016, 
2:45 PM) http://www.sciencemag.org/news/2016/12/under-21st-century-cures-legislation-stem-cell-
advocates-expect-regulatory-shortcuts-0 [https://perma.cc/Z95R-6QN6]. An example of a surrogate 
endpoint is blood pressure in a trial for antihypertensive drugs. IOM, BIOMARKERS, supra, at 3 box S-2. 
 292. Aaron Kesselheim, Sana R. Mostaghim & Joshua J. Gagne, Safety Related Label Changes for 
New Drugs After Approval in the US through Expedited Regulatory Pathways: Retrospective Cohort 
Study, 358 BMJ 1 (2017); Ed Silverman, Speedy FDA Drug Reviews Also Yield More Safety Changes to 
Labeling, STAT (Sept. 14, 2017), https://www.statnews.com/pharmalot/2017/09/14/fda-drug-reviews-
safety-changes/ [https://perma.cc/MTP8-HJDJ]. 
 293. Kesselheim, Mostaghim & Gagne, supra note 292; Silverman, supra note 292. 
 294. See generally Nicholas S. Downing et al., Postmarket Safety Events Among Novel Therapeutics 
Approved by the US Food and Drug Administration Between 2001 and 2010, 317 JAMA 1854 (2017). 
 295. Behnood Bikdeli et al., Two Decades of Cardiovascular Trials with Primary Surrogate 
Endpoints: 1990–2011, 116 J. AM. HEART ASS’N 1, 1 (2017). 
 296. Eugene J. Sullivan, Chief Med. Officer, United Therapeutics and Lung Rx, Presentation at the 
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recent study of 220 cardiovascular clinical trials using surrogate 
endpoints found that although over 70% of the trials demonstrated 
the positive surrogate endpoint, only slightly more than a quarter 
were followed with a clinical trial testing the clinical endpoint.297 
And of these trials testing the clinical endpoint, nearly half failed to 
demonstrate the clinical endpoint predicted by the surrogate 
endpoint.298 The authors concluded that their findings “raise concern 
about the certainty of assuming efficacy based on surrogate 
endpoints. Even if used for approval of therapies in urgent situations, 
postmarketing outcome trials are necessary.”299 
These studies show that determining the true risk/benefit ratio of a 
regenerative medicine therapy based on studies with surrogate or 
intermediate clinical endpoints is less certain, because both the 
benefit and the risk may not be as fully explored in a trial that looks 
only at surrogate or intermediate clinical endpoints. The benefit must 
be extrapolated from the observed surrogate effect; the risks may not 
all be revealed in shorter, smaller studies.300 
The existing challenges facing biologics in Phase 3 trials or under 
current accelerated pathways should give us pause before expanding 
the number of products approved based on early-stage clinical 
evidence. The regulatory system must acknowledge the trade-offs 
between faster access and safety. And until the expedited clinical trial 
process is better able to predict harms, limiting expedited review to 
those treatments that seek to address life-threatening conditions or 
unmet medical needs reflects a more reasonable balance between the 
FDA’s goals of protecting public health and advancing beneficial 
innovation. 
                                                                                                                 
FDA’s 2013 Clinical Investigator Training Course: Clinical Trial Endpoints (Nov. 12, 2013), 
http://www.fda.gov/downloads/Training/ClinicalInvestigatorTrainingCourse/UCM283378.pdf 
[https://perma.cc/FCS3-WJGT]. 
 297. Bikdeli et al., supra note 295, at 3. 
 298. Id. 
 299. Id. at 7. 
 300. Sullivan, supra note 296. 
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4.   A Question of Timing? 
The principles of adaptive regulation contain an implicit fourth 
requirement: that the principles align at an opportune time for reform. 
In this sense, adaptive licensing may simply be an idea whose time 
has not yet come. Many of the roadblocks discussed in the previous 
section are surmountable. Where the FDA lacks authority, Congress 
can grant it. Sponsors and the FDA can negotiate, test, and revise 
their agreements. Concerns with payors can be worked through with 
input from affected parties. 
But the safety concerns remain. With time, however, these 
roadblocks may also be surmountable. As regulatory science 
advances and coincides with a deeper understanding of how 
regenerative medicine therapies work, it may be possible to validate 
new surrogate endpoints or harness electronic health records in a way 
that offers greater assurances of safety and efficacy. The accelerated 
approval pathways, including RMAT designation, provide a 
laboratory for experimentation with the sources and content of data to 
improve the predictive ability of early safety and efficacy data. And 
this, in itself, is a form of adaptive management: defining the 
problem that early-stage trial data does not sufficiently predict later 
health and safety concerns, setting a goal to improve the data’s 
predictive power, implementing various regulatory tools, and 
evaluating each for success. 
If we reach this goal, it will be worth revisiting adaptive licensing. 
But until that hypothetical opportune moment, implementing 
adaptive licensing for regenerative medicine therapies is unworkable 
and unwise for a variety of reasons, including: 
 
 Insufficient or unclear FDA authority to approve 
biologics based on evidence that does not support 
the continued safety, purity, and potency of the 
product (except for products approved under 
Congressionally-authorized accelerated pathways); 
 Insufficient or unclear authority of the FDA to 
require postmarketing obligations for regenerative 
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medicine products regulated as biologics (except for 
new safety issues or under a Congressionally-
authorized accelerated pathway); 
 Political difficulties in removing products from the 
marketplace, especially if based on a sponsor’s 
violation of protocol as opposed to newly-
discovered safety or effectiveness issues; 
 Hurdles to incentivizing sponsor participation, 
especially involving payment; and 
 Risks to patients who receive regenerative medicine 
therapies that have not undergone thorough Phase 3 
testing. 
 
Given these impediments and challenges, the benefits derived from 
adaptive licensing do not outweigh the risks to patients and the costs 
of reform. 
IV.   Incremental Changes to Existing Regulations: Reform of Section 
361 Products 
In the previous section, I argued against adopting adaptive 
licensing for those regenerative medicine products regulated as 
biologics. In this section, I recommend reforming regenerative 
medicine therapies regulated as section 361 products by expanding 
the same surgical procedure exception and expanding the scope of 
section 361. Whereas the reform proposals for biologics were 
dramatic and would involve congressional action, FDA rulemaking, 
and a fundamental change in the meaning of premarket approval, the 
proposed reforms to the regulation of section 361 products are more 
modest. The proposals simply involve updating the interpretation of 
key statutory terms based on evolving scientific understanding. 
A.   FDA’s Guidance on Section 361 Products 
Because the FDA’s regulatory requirements are most burdensome 
for regenerative medicine therapies regulated as biologics, 
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manufacturers often seek to have their products categorized into the 
lowest or middle regulatory tier.301 To this end, manufacturers 
recently asked the FDA to clarify certain section 361 requirements, 
and the FDA responded by issuing guidance documents302 to explain 
the FDA’s positions on the same surgical procedure exception;303 the 
meaning of homologous use;304 the meaning of minimal 
manipulation;305 and how the regulations apply to products derived 
from adipose tissues.306 
Although guidance documents are not legally binding, the FDA 
issues them to communicate its expectations to the industry and to 
stakeholders.307 Guidance documents assist the industry by providing 
clarity and consistency.308 Under the Good Guidance Principles 
adopted in 2000, the process for issuing a guidance document 
requires the FDA to publish a draft guidance and notify the public of 
its availability in hard copy and on the internet.309 The public is 
invited to submit comments, and after a time, the FDA reviews the 
comments and prepares a final draft that need not, but may as 
appropriate, address the public’s comments.310 The draft guidances 
contain a number of clarifications and explanations of the section 361 
requirements. 
                                                                                                                 
 301. CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 69. 
 302. Id. at 9. 
 303. U.S. FOOD & DRUG ADMIN., SAME SURGICAL PROCEDURE EXCEPTION UNDER 21 C.F.R. 
1271.15(B): QUESTIONS AND ANSWERS REGARDING THE SCOPE OF THE EXCEPTION: DRAFT GUIDANCE 
FOR INDUSTRY (2014) [hereinafter FDA DRAFT GUIDANCE ON SAME SURGICAL PROCEDURE]. 
 304. FDA DRAFT GUIDANCE ON HOMOLOGOUS USE, supra note 56. 
 305. FDA DRAFT GUIDANCE ON MINIMAL MANIPULATION, supra note 55. 
 306. U.S. FOOD & DRUG ADMIN., HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE BASED 
PRODUCTS (HCT/PS) FROM ADIPOSE TISSUE: REGULATORY CONSIDERATIONS DRAFT GUIDANCE OF 
INDUSTRY (2014) [hereinafter FDA DRAFT GUIDANCE ON ADIPOSE TISSUE]. 
 307. See 21 C.F.R. § 10.115(d) (2012) (“Guidance documents do not establish legally enforceable 
rights or responsibilities. They do not legally bind the public or FDA.”); id. § 10.115(g) (setting out 
procedures for Level 1 guidance documents). 
 308. Erica Seiguer & John J. Smith, Perception and Process at the Food and Drug Administration: 
Obligations and Trade-Offs in Rules and Guidances, 60 FOOD & DRUG L.J. 17, 30 (2005). 
 309. Id. at 21. 
 310. See 21 C.F.R. § 10.115. 
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1.   Same Surgical Procedure Draft Guidance 
In this draft guidance, the FDA clarifies when a product is 
excepted from the requirements applicable to section 361 products. 
The exception is codified in section 1271.15(b): “You are not 
required to comply with the requirements of this part if you are an 
establishment that removes [cell or tissue products] from an 
individual and implants such [cell or tissue products] into the same 
individual during the same surgical procedure.”311 The guidance 
clarifies that only a very limited number of steps may be performed 
on the cells or tissues outside of the body to qualify for the same 
surgical procedure exception. Specifically, the language of “such 
[cell or tissue products]” means that the cell or tissue product can 
only be “rinsed, cleaned, sized, or shaped.”312 Any other processing 
will cause the manufacturer to lose the same surgical procedure 
exception.313 
The FDA’s rationale for limiting the scope of the exception rests 
on the risk of infectious disease transmission.314 Steps taken when the 
cells are processed, preserved, or removed from storage raise 
contamination concerns beyond those typically associated with 
surgery.315 Thus, any such steps require the manufacturer to follow 
the requirements that apply to section 361 products or biologics. 
2.   Minimal Manipulation Draft Guidance 
To qualify as a section 361 cell or tissue product, a product cannot 
be more than minimally manipulated.316 The regulatory definition of 
minimal manipulation depends on whether the therapy uses a 
“structural tissue” or “cells or nonstructural tissue.”317 If the tissue is 
structural, minimal manipulation is “processing that does not alter the 
original relevant characteristics of the tissue relating to the tissue’s 
                                                                                                                 
 311. 21 CFR § 1271.15(b) (emphasis added). 
 312. FDA DRAFT GUIDANCE ON SAME SURGICAL PROCEDURE, supra note 303, at 3 n.4. 
 313. Id. at 3. 
 314. Id. 
 315. Id. at 5. 
 316. Ravitz, Halpern & Leongini, supra note 54. 
 317. 21 C.F.R. § 1271.3(f)(1)–(2) (2004). 
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utility for reconstruction, repair, or replacement.”318 In nonstructural 
tissue, minimal manipulation is “processing that does not alter the 
relevant biological characteristics of cells or tissues.”319 
The minimal manipulation draft guidance provides examples of 
minimal manipulation and provides general principles for application 
to other or future products.320 First, because the regulations set 
different standards for minimal manipulation depending on whether 
the tissue is structural or non-structural,321 the guidance clarifies 
these terms. Structural tissue supports and serves “as a barrier or 
conduit, or connect[s], cover[s], or cushion[s].”322 Examples of 
structural tissue include bone, skin, blood vessels, adipose (fat) 
tissue, articular cartilage, non-articular cartilage, and tendons or 
ligaments.323 Nonstructural tissues are “those that serve 
predominately metabolic or other biochemical roles in the body such 
as hematopoietic, immune and endocrine functions,” and include 
reproductive cells or tissues, cord blood, and pancreatic tissue, to 
name a few.324 
Second, the draft guidance explains the standards for minimal 
manipulation by explaining and illustrating the foundational concepts 
of (1) structural tissues’ original relevant characteristics relating to its 
utility for reconstruction, repair, or replacement, and (2) non-
structural tissues’ relevant biological characteristics.325 For instance, 
stem cells isolated from adipose tissue are more than minimally 
manipulated.326 This is because, according to the FDA, fat is a 
structural tissue, and its original relevant characteristics of padding 
and cushioning are based on its bulk and lipid storage capacity.327 
Processing for stem cell extraction breaks down and eliminates the 
                                                                                                                 
 318. Id. at § 1271.3(f)(1). 
 319. Id. at § 1271.3(f)(2). 
 320. FDA DRAFT GUIDANCE ON MINIMAL MANIPULATION, supra note 55, at 3, 5, 8. 
 321. Id. at 3. 
 322. Id. at 4. 
 323. Id. at 5. 
 324. Id. at 8. 
 325. Id. at 3. 
 326. FDA DRAFT GUIDANCE ON MINIMAL MANIPULATION, supra note 55, at 6. 
 327. Id. at 5–6. 
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structural components that provide cushioning and support, so the 
product is considered more than minimally manipulated.328 
If a product is more than minimally manipulated, it loses section 
361 status and is subject to regulation as a drug or biologic.329 The 
rationale is that products that are more than minimally manipulated 
have the potential to, or are intended to, change the cell or tissue’s 
biological characteristics or functions, which raises concerns about 
the product’s ultimate safety or effectiveness.330 
3.   Homologous Use Draft Guidance 
A section 361 product must be intended for homologous use.331 
This means that the cells or tissues in the recipient must perform the 
same basic function in the recipient as in the donor.332 This 
requirement addresses the concern that non-homologous uses raise 
safety and effectiveness concerns due to the diminished basis on 
which to predict the product’s behavior.333 The requirement applies 
to both allogenic and autologous uses.334 In other words, there is no 
exception to this requirement even when the tissue is taken from and 
re-implanted into the same patient.335 
The draft guidance clarifies terms and provides several examples. 
When the tissue is used for the exact same purpose in the donor and 
the recipient, the use is homologous; for example, a heart valve 
transplanted to replace a recipient’s dysfunctional heart valve is a 
homologous use.336 A use in the recipient that has the same basic 
function as the use in the donor also qualifies.337 For example, the use 
of a pericardium (the membrane around heart) as a wound covering 
for defects of the dura mater (the membrane enveloping brain and 
                                                                                                                 
 328. Id. at 8. 
 329. Id. at 2–3. 
 330. PROPOSED APPROACH TO REGULATION OF CELLULAR AND TISSUE-BASED PRODUCTS, supra note 
48, at 9721. 
 331. 21 C.F.R. § 1271.10(a)(2) (2004). 
 332. Id. § 1271.3(c). 
 333. FDA DRAFT GUIDANCE ON HOMOLOGOUS USE, supra note 56, at 3. 
 334. Id. at 2. 
 335. See id. 
 336. Id. at 4. 
 337. Id. 
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spinal cord) is a homologous use because it serves as a covering in 
both its original form and in the recipient.338 Uses that are not the 
same in the donor and recipient are not considered homologous.339 
For example, because the basic function of hematopoietic stem cells 
is to form and replenish the blood system, any use outside of this 
purpose—like infusion to treat cerebral palsy—is not homologous.340 
The FDA also clarifies that if the cell or tissue product is intended for 
use as an unproven treatment for a myriad of diseases or conditions, 
the use is not homologous.341 
4.   Adipose Tissue Products Draft Guidance 
In this draft guidance, the FDA specifically explains the section 
361 requirements as applied to products derived from adipose (fat) 
tissue.342 Adipose tissue is the most common source of stem cells 
used in unapproved stem cell therapies.343 The FDA “recently 
received numerous inquiries regarding [cell or tissue products] 
manufactured from adipose tissues.”344 In this draft guidance, the 
FDA states that it generally considers adipose tissue to be a structural 
tissue because it is a “connective tissue that stores energy in the form 
of lipids, insulates the body, and provides cushioning and support for 
subcutaneous tissues and internal organs.”345 It is composed 
primarily of adipocyte cells, but also contains a number of other cell 
types.346 
The guidance applies the section 361 requirements to adipose 
tissue. The FDA states that it considers adipose tissue more than 
minimally manipulated when it is processed to isolate the non-fat 
cells from the tissue.347 This means that the procedures stem cell 
                                                                                                                 
 338. See id. 
 339. See FDA DRAFT GUIDANCE ON HOMOLOGOUS USE, supra note 56, at 4. 
 340. See id. at 5. 
 341. See id. at 6. 
 342. FDA DRAFT GUIDANCE ON ADIPOSE TISSUE, supra note 306, at 1. 
 343. Turner & Knoepfler, supra note 23, at 156. 
 344. Id. at 2. 
 345. Id. at 1. 
 346. Id. at 1–2. 
 347. Id. at 3. 
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clinics use to extract stem cells from adipose tissue are generally 
considered more-than-minimal manipulation.348 In clarifying the 
homologous use requirement, the draft guidance states that the FDA 
would likely consider the use of adipose tissue as a cosmetic filler 
homologous use because this use reflects a basic function of adipose 
tissue: to support subcutaneous tissues.349 But the FDA would not 
consider the use of the tissue to treat bone and joint disease a 
homologous use because the tissue does not perform this function in 
the donor.350 
These examples demonstrate that the FDA does not consider the 
products provided by stem cell clinics to meet the section 361 
requirements of minimal manipulation and homologous use. The 
stem cell clinics generally isolate the non-fat cells for implantation, 
which the FDA defines as more than minimal manipulation.351 And 
the clinics advertise the stem cell-derived products for functions 
other than those traditionally performed by adipose tissue, which the 
FDA interprets as non-homologous use.352 
Furthermore, the draft guidance clarifies that the stem cell clinics’ 
products are unlikely to fall within the same surgical procedure 
exception.353 This is because the exception considers cells to be the 
same cells (as expressed in the regulation, “such [cell or tissue 
products]”) only if they are rinsed and cleansed to remove debris.354 
Because the stem cell clinics typically engage in additional steps such 
as cell isolation, cell expansion, or enzymatic digestion, the products 
are not covered under the same surgical procedure exception.355 
                                                                                                                 
 348. Id. at 4. 
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 351. Id. at 6. 
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 353. Id. at 8. 
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B.   Reforms to Expand the Scope of Section 361 and the Same 
Surgical Procedure Exception 
1.   Treatment of Autologous Therapies 
a.   Existing Proposals Suggest Treating Autologous 
Therapies as Exceptional 
Several proposals for reform address the scope of section 361. A 
common theme among these proposals is to treat therapies that use 
the patient’s own cells as source material, an autologous use, 
differently from those that use a donor’s cells. This distinction is 
already partly captured in existing regulations: any use of cell or 
tissue products that affects the body systemically or depends on cell 
metabolism does not qualify for section 361 unless the cells come 
from a donor (or a first- or second-degree relative).356 But reformers 
want to see a greater distinction in the legal treatment of these uses. 
Professor Mary Ann Chirba and attorney Stephanie Garfield have 
argued that autologous therapies that are either developed or used by 
practicing physicians should be exempt from regulation or, 
alternatively, should be regulated under a more flexible framework 
than therapies developed by pharmaceutical companies.357 Failure to 
do so, they argued, will harm innovation, disrespect patient 
autonomy, and hamper the public’s health.358 Attorney Greg Pivarnik 
came to a similar conclusion but for a different reason. He argued 
that although the FDA has the legal authority to regulate autologous 
stem cell treatments, it should decline to do so.359 He reasoned that 
the information asymmetry between pharmaceutical companies and 
patients justified premarket approval for traditional drugs and 
allogenic therapies, but that the personal doctor–patient relationship 
assuages fears that patients will make uniformed choices.360 
                                                                                                                 
 356. 21 C.F.R. § 1271.10 (2017). 
 357. Chirba & Garfield, supra note 109, at 253. 
 358. Id. at 268. 
 359. Greg Pivarnik, Cells as Drugs? Regulating the Future of Medicine, 40 AM. J. L. & MED. 298, 
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Furthermore, to the extent that doctors breach their duties to the 
patient, Pivarnik argued, state regulations and tort laws effectively 
address these concerns.361 Other commentators, however, have 
disagreed and argued that autologous therapies should remain subject 
to FDA oversight because of their risks of contamination and 
infection.362 Professor Barbara von Tigerstrom noted unique 
challenges with regulating autologous therapies, but argued that FDA 
regulation is still needed to ensure that the therapies are safe and 
effective.363 
A more nuanced approach was offered by Jay Segal, chief 
biotechnology officer and head of scientific strategy and policy for 
Johnson & Johnson, during the FDA’s hearing.364 Segal argued that 
the same surgical procedure exception should be applied more 
broadly to include autologous cell products that were minimally 
manipulated.365 The current regulations provide that only autologous 
therapies that are rinsed, cleansed, sized, and shaped are covered by 
the same surgery exception.366 Siegel argued that the current 
distinction between these products and products that undergo other 
“minimal” procedures, which are currently not allowed under the 
same surgical procedure exception, is not sound based on the cell or 
tissue product’s risk of contamination and transmission of infectious 
diseases.367 Furthermore, he argued that existing regulations of 
surgical facilities ensure that these facilities have procedures in place 
to prevent the spread of communicable disease—so regulation of the 
entities as manufacturers of section 361 products is unnecessary and 
duplicative.368 
 
                                                                                                                 
 361. Id. at 320. 
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b.   Autologous Therapies Should Not All Be Exempt from 
FDA Regulation, but Expansion of the Same Surgical 
Procedure Exception Is Justified 
Reform proposals that promote removing all autologous therapies 
from FDA regulation are misguided. Under the current system, some 
autologous therapies where the cells are only rinsed, cleansed, sized, 
or shaped are exempt from FDA regulation;369 some where the cells 
are not more than minimally manipulated and are for homologous use 
are subject to the communicable disease regulations of section 
361;370 and some that are more than minimally manipulated or not for 
homologous use are subject to regulation as biologics.371 Working 
backward from the most restrictive to the least restrictive levels of 
regulation, it would be foolish to exempt all autologous regenerative 
medicine therapies from regulation as biologics. When a cell-based 
product is intended for a different purpose than the cells originally 
placed in the body, or when the cells have been altered in a way that 
affects their relevant characteristics, we do not know how the cells 
will function in the recipient absent clinical evidence.372 And not 
only might the autologous therapies not work, they might cause 
physical harm.373 Former FDA Commissioner Robert Califf 
described two instances in which autologous therapies likely caused 
patient harms.374 In one instance, autologous hematopoietic stem 
cells that were injected into a patient with kidney failure were 
associated with the formation of tumors.375 In a separate instance, 
autologous stem cells derived from adipose tissue and injected into 
the eyes of three patients with macular degeneration were associated 
with worsening vision in all three.376 
Removing all autologous therapies from section 361 regulations is 
also unwise. Minimal manipulation of cells—including banking, 
                                                                                                                 
 369. Id. at 88–89. 
 370. CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 88–89. 
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transporting, or processing—risks the transmission of communicable 
disease because the products are susceptible to contamination or mix-
ups.377 For example, an infected product could cross-contaminate 
other products stored in the same liquid nitrogen in a freezer. 
Similarly, a product could contaminate processing equipment.378 The 
current Good Tissue Practice requirements that apply to all section 
361 products set forth the procedures and controls to prevent such 
contamination.379 Furthermore, it is not at all clear that the 
regulations that govern hospitals and ambulatory surgical centers are 
sufficient to guard against viral and bacterial contamination.380 
On the other hand, the FDA may be able to expand the same 
surgical procedure exception in some instances. For example, if 
certain processing techniques involve more manipulation than 
rinsing, cleansing, sizing, or shaping but do not increase the risk of 
contamination, such processes could be captured under the same 
surgical procedure exemption. For example, if the FDA determined 
that a certain closed processing system, or storage in liquid nitrogen 
vapors as opposed to the liquid, did not increase the risk of 
contamination, such processing steps could be captured under the 
same surgical procedure exception without compromising the 
purpose of the exception. 
2.   Expanding the Scope of Section 361 
A second path to speeding products to market is to allow more 
therapies to qualify as section 361 products. This would permit the 
                                                                                                                 
 377. PROPOSED APPROACH TO REGULATION OF CELLULAR AND TISSUE-BASED PRODUCTS, supra 
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manufacturers of these products to meet only the lighter requirements 
of section 361: registering with the FDA and implementing 
procedures to avoid contamination and the transmission of infectious 
disease.381 Section 361 cell or tissue products avoid the lengthy 
clinical trials required to prove safety and effectiveness, or purity and 
potency, required for drugs and biological products.382 A 
liberalization of section 361’s requirements could occur if the FDA 
more loosely interpreted the homologous use and minimal 
manipulation requirements. For example, the homologous use 
requirement, as currently interpreted, states that adipose tissue used 
to fill in the hollows of the cheeks is a homologous use, but the use of 
the same tissue in breast reconstruction is not a homologous use. This 
is because, as stated by the FDA, the “basic function of breast tissue 
is to produce milk (lactation) after childbirth.”383 And, because 
lactation is not a basic function of adipose tissue, such use would not 
be covered under section 361.384 A more liberal interpretation might 
allow for multiple basic function determinations of both the donated 
and recipient tissues.385 Similarly, the FDA could soften the minimal 
manipulation requirement. Currently, decellularization generally 
renders adipose tissue more than minimally manipulated because it 
alters its “original relevant characteristics” relating to its “utility for 
reconstruction, repair, or replacement.”386 Because decellularization 
removes adipose tissue’s bulk, it no longer provides cushioning and 
support, which are its original relevant characteristics.387 But if the 
FDA accepted other original relevant characteristics of adipose 
tissue, such as its paracrine function, additional therapies would meet 
the minimal manipulation requirement.388 
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To the extent that a tissue or cell has multiple basic functions, the 
FDA should expand the homologous use requirement. Similarly, to 
the extent scientific evidence supports multiple original relevant 
characteristics for cells or tissues, the FDA should expand the 
minimal manipulation requirement. This will allow additional 
products that do not raise drug-level safety and effectiveness 
concerns to receive the lighter regulatory touch of section 361. 
CONCLUSION 
Reform is in the air. Industry representatives, patients and their 
advocates, politicians, and regulators are analyzing and advocating 
for changes to the regenerative medicine regulatory framework to 
best address how to bring innovative therapies to patients while 
avoiding common or foreseeable patient harms. 
Significant reforms of the product approval framework for 
regenerative medicine therapies regulated as biologics have been 
proposed; they are impracticable and unwise. Existing proposals fall 
short because they fail to address problems with the FDA’s authority, 
implementation challenges, and most significantly, safety and 
efficacy concerns. Continued study of lifecycle approaches, however, 
is warranted, because advances in regulatory science and regenerative 
medicine may enable the FDA to implement adaptive licensing with 
greater assurances of safety and effectiveness. 
For moderate-risk products, although proposals that drastically 
expand the scope of products exempted from regulation are unwise, 
more incremental proposals that expand the same surgical procedure 
exception and the scope of products regulated under section 361 can 
be implemented without damaging section 361’s underlying goals of 
avoiding contamination and the transmission of infectious disease. 
The current system is not broken. Harnessing the body’s ability to 
heal itself and translating this understanding into clinical practice is 
complicated and time-consuming, and the current framework already 
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provides regulatory flexibility depending on a therapy’s risks. 
Implementing regulatory shortcuts that will risk harming patients is 
not the answer, but neither is treating the current system as set in 
stone. Instead, advances in scientific understanding warrant 
incremental changes to the existing section 361 framework. And 
although an overhaul of the biologics framework is premature, 
advances in regulatory science and increased understanding of 
regenerative medicine may one day justify such an undertaking. 
The next few years will bring significant advances to the 
regenerative medicine field, and its regulation must be flexible to 
keep pace. Whether the reforms are incremental or more 
transformative, measures taken now can ensure continued patient 
protection while advancing access to therapies when it is safe and 
appropriate.
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